

CITATION REPORT

List of articles citing

Graft-versus-leukemia reactions after bone marrow transpla

DOI: 10.1182/blood.v75.3.555.555
Blood, 1990, 75, 555-562.

Source: <https://exaly.com/paper-pdf/21536522/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2323	Allogeneic Bone Marrow Transplantation: A Review. 1990 , 3, 11-22		1
2322	Options for the Management of Chronic Myeloid Leukaemia-1990. 1990 , 3, 159-64		10
2321	Can Long-Term Bone Marrow Culture Eliminate Leukemia Cells?. 1990 , 3, 87-91		2
2320	Autotransplants in chronic myelogenous leukaemia: strategies and results. 1990 , 335, 1255-8		62
2319	Interleukin-2: prospects for lymphocyte-mediated destruction of pediatric malignancies. 1991 , 118, S14-6		
2318	Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. 1991 , 338, 1315-8		42
2317	Detecting minimal residual leukemia. 1991 , 52, 19-26		4
2316	Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation. 1991 , 57, 69-78		20
2315	A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. 1991 , 21, 850-6		25
2314	Allogeneic bone marrow transplantation: Procedures and complications. 1991 , 48, 127-137		
2313	Graft-versus-host reactions and bone-marrow transplantation. 1991 , 3, 752-7		19
2312	What does total body irradiation do in bone marrow transplants for leukemia?. 1991 , 20, 631-4		30
2311	Response to Vriesendorp et al. 1991 , 20, 645-6		3
2310	Therapy of advanced acute myeloblastic leukemia with cytarabine and interleukin 2. 1991 , 15, 759-63		4
2309	Production of tumour-derived suppressor factor in patients with acute myeloid leukaemia. 1991 , 15, 263-8		17
2308	Autotransplants in leukemia: current state, future progress. 1991 , 15, 781-4		8
2307	Bone marrow transplant for acute leukaemia. 1991 , 4, 483-510		2

2306	Control of relapse due to minimal residual disease (MRD) by cell-mediated cytokine-activated immunotherapy in conjunction with bone marrow transplantation. 1991 , 4, 715-25	8
2305	Graft versus leukaemia effects after marrow transplantation in man. 1991 , 4, 727-49	8
2304	Autotransplants in acute leukaemia. 1991 , 78, 135-7	12
2303	Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation. 1991 , 77, 60-5	7
2302	Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high-risk features. 1991 , 67, 1830-7	24
2301	Evaluation of in vitro cytotoxic T lymphocyte assays as a predictive test for the occurrence of graft vs host disease. 1991 , 34, 222-6	15
2300	Peripheral Blood Stem Cell Autografts in Children with Acute Lymphoblastic Leukemia and Lymphoma: Updated Experience. 1991 , 3, 241-56	15
2299	Serial Detection of Residual bcr/abl mRNA by Polymerase Chain Reaction in Patients with Chronic Myelogenous Leukemia after Bone Marrow Transplantation. 1991 , 4, 263-9	4
2298	Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. 1991 , 325, 1267-73	306
2297	Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies. 1992 , 8, 421-9	5
2296	Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. 1992 , 10, 221-7	38
2295	Bone marrow transplantation for acute non-lymphoblastic leukemia. 1992 , 7, 7-14	1
2294	Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. 1992 , 10, 19-26	54
2293	Cancer immunotherapy: are the results discouraging? Can they be improved?. 1992 , 59, 245-322	60
2292	Non HLA-Restricted Cytotoxic Cells and Their Modulation in Acute Myelogenous Leukemia. 1992 , 6, 449-457	
2291	Counterflow centrifugal elutriation: experimental and clinical applications. 1992 , 1, 279-88	6
2290	Autologous graft-versus-host disease: a novel approach for antitumor immunotherapy. 1992 , 34, 219-24	24
2289	Graft vs. leukaemia reactions in chronic myeloid leukaemia. 1992 , 28A, 2069-74	2

2288	Current status of allogeneic bone marrow transplantation. 1992 , 46, 57-69	4
2287	Acute myelogenous leukemia: current treatment and future directions. 1992 , 92, 286-95	28
2286	Preclinical Evaluation of a Bone-Marrow Autograft Culture Procedure for Generating Lymphokine-Activated Killer Cells in Vitro. 1992 , 3, 123-127	3
2285	Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation. 1992 , 13, 151-5	15
2284	Graft versus leukemia. 1992 , 11, 24-33	14
2283	Biological aspects and clinical results of autologous bone marrow transplantation for acute myeloid leukemia. 1992 , 22, 185-9	
2282	Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease. 1992 , 64, 255-9	31
2281	Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning. 1992 , 80, 33-9	34
2280	Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. 1992 , 82, 708-14	34
2279	Second bone marrow transplantation for leukemic relapse without graft-vs.-host disease prophylaxis. 1993 , 43, 324-5	3
2278	Potential role for non-HLA-restricted cytotoxic cells in the immune surveillance of acute leukemia. 1993 , 39, 13-5	6
2277	Plotting summary predictions in multistate survival models: probabilities of relapse and death in remission for bone marrow transplantation patients. 1993 , 12, 2315-32	64
2276	Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. 1993 , 84, 67-74	134
2275	Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: a comparison of transplant versus no-transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. 1993 , 85, 292-9	15
2274	The challenge of acute lymphoblastic leukaemia in adults. 1993 , 85, 641-5	5
2273	Transfusion-associated graft-versus-host disease: report of an occurrence following the administration of irradiated blood. 1993 , 33, 524-9	59
2272	The pharmaceuticals and delivery of therapeutic polypeptides and proteins. 1993 , 10, 247-299	52
2271	Mechanisms of allogeneic stimulation induced tumor necrosis factor-alpha (TNF-alpha) production. 1993 , 17, 89-95	2

2270	Is there a place for autologous bone marrow transplantation in chronic myeloid leukemia?. 1993 , 11 Suppl 3, 1-3	17
2269	Autografting in chronic myelogenous leukemia followed by immunotherapy. 1993 , 11 Suppl 3, 34-42	14
2268	Biological strategies for the selective manipulation of normal and leukemic stem cells. 1993 , 11 Suppl 3, 109-21	16
2267	Immune reconstitution following bone marrow transplantation. 1993 , 37, 351-60	20
2266	[Immunologic aspects of bone marrow transplantation]. 1993 , 36, 339-73	
2265	T-cell depletion for allogeneic bone marrow transplantation: impact on graft-versus-host disease, engraftment, and graft-versus-leukemia. 1993 , 2, 27-42	16
2264	High dose therapy for acute myelocytic leukemia treatment strategy: what is the choice?. 1993 , 4 Suppl 1, 59-80	6
2263	The role of bone marrow transplantation in adult acute lymphocytic leukemia. 1993 , 4 Suppl 1, 81-90	8
2262	Graft-versus-leukemia reactions in clinical bone marrow transplantation. 1993 , 10, 427-32	27
2261	Recurrence of Philadelphia chromosome-positive leukemia in donor cells after bone marrow transplantation for chronic granulocytic leukemia. 1993 , 10, 419-25	20
2260	Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. 1993 , 329, 757-61	88
2259	Treatment of CML with unrelated donor marrow transplant. 1993 , 11 Suppl 1, 209-11	3
2258	Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide. 1993 , 11, 321-9	16
2257	Prognostic factors in chronic myeloid leukemia. Relationship with interferon and bone marrow transplantation. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. 1993 , 11 Suppl 1, 67-71	4
2256	Natural killer cells and bone marrow transplantation. 1993 , 85, 1475-82	50
2255	Is there any future for T-cell depleted bone marrow transplantation in chronic myeloid leukaemia?. 1993 , 11 Suppl 1, 205-7	
2254	The graft versus leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogenous leukemia (CML). 1993 , 11 Suppl 1, 221-6	40
2253	Clinical models of autotransplants in chronic myelogenous leukemia. 1993 , 11 Suppl 1, 255-7	2

2252	Current thoughts on the pathogenesis of graft versus host disease. 1993 , 46, 785-9	15
2251	Improving the role of hematopoietic support for high-dose cytotoxic therapy. 1993 , 11, 319-26	1
2250	Bone Marrow Transplantation for Hematological Diseases in Hokkaido—June 1985 to December 1991. 1993 , 23, 166-172	1
2249	Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. 1993 , 11, 513-9	137
2248	Role of Autologous Bone Marrow Transplantation for Patients with Acute and Chronic Leukemias. 1993 , 7, 547-575	1
2247	Allogeneic Bone Marrow Transplantation for the Treatment of Adult Acute Leukemias. 1993 , 7, 177-200	10
2246	Hematopoietic Growth Factors in Bone Marrow Transplantation: Role in Purging, Graft Engineering, Stem Cell Mobilization, and Hematologic Recovery. 1994 , 273-283	
2245	Tumor immunity: will new keys unlock the door?. 1994 , 12, 237-8	10
2244	Mononuclear Cell Adoptive Immunotherapy. 1994 , 8, 1203-1222	6
2243	CAMPATH-1 monoclonal antibodies in bone marrow transplantation. 1994 , 3, 15-31	59
2242	Bone marrow transplantation. 1994 , 330, 827-38	579
2241	Understanding the mechanism of cure of acute myeloid leukemia by allogeneic bone marrow transplantation: toward the application of interleukin-2 in autologous bone marrow transplantation. 1994 , 3, 47-50	6
2240	Bone marrow transplantation in leukemia. 1994 , 3, 235-8	4
2239	Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus, bone marrow, spleen and blood of mice following split-dose polychemotherapy. 1994 , 39, 59-67	15
2238	The management of chronic graft-versus-host disease. 1994 , 8, 154-60	46
2237	Treatment of hematological malignancies relapsing after allogeneic bone marrow transplantation. 1994 , 8, 234-40	9
2236	Bone marrow transplantation for acute lymphoblastic leukemia (ALL). 1994 , 11, 75-88	6
2235	Haematological applications of interleukin-2 and other immunostimulatory cytokines. 1994 , 7, 115-34	1

2234	Bone marrow transplantation for acute lymphoblastic leukaemia. 1994 , 7, 377-401	15
2233	Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome. 1994 , 86, 62-9	46
2232	Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. 1994 , 330, 100-6	428
2231	Graft-versus-host disease and the development of late complications. 1994 , 15, 243-54	7
2230	Immunological Therapy of Breast Cancer. 1994 , 1, 135-147	1
2229	Identical-twin bone marrow transplants for leukemia. 1994 , 120, 646-52	210
2228	Unrelated donor bone marrow transplants in children. 1994 , 3, 413-20	12
2227	Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting. 1995 , 104, 510-6	6
2226	Expansion of CD8+CD57+ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. 1995 , 90, 300-7	49
2225	Persistence of multilineage host haemopoiesis following allogeneic bone marrow transplantation. 1995 , 90, 465-8	5
2224	T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. 1995 , 89, 506-15	130
2223	Transplantation of T-lymphocyte depleted marrow with an addback of T cells. 1995 , 13, 219-24	4
2222	Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. 1995 , 10, 139-43	3
2221	Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. 1995 , 71, 209-17	7
2220	New and experimental therapies for treating graft-versus-host disease. 1995 , 9, 117-33	21
2219	Hematopoietic stem cell transplantation for cancer therapy. 1995 , 7, 687-93	10
2218	Autologous graft-versus-host disease. 1995 , 12, 149-56	
2217	Role of interleukin-2 in human hematological malignancies. 1995 , 12, 177-86	9

2216	Bone marrow-derived T-cell clones obtained from untreated acute myelocytic leukemia exhibit blast directed autologous cytotoxicity. 1995 , 19, 73-82	26
2215	Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. 1995 , 13, 1704-13	35
2214	Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. 1995 , 13, 1312-22	246
2213	Novel cellular therapies. 1995 , 24, 411-20	2
2212	Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia?. 1995 , 16, 397-405	13
2211	Introducing graft-versus-leukemia into autologous stem cell transplantation. 1995 , 4, 261-7	1
2210	Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. 1995 , 332, 217-23	719
2209	The role of natural killer cells in the treatment of chronic myeloid leukemia. 1995 , 4, 269-79	7
2208	Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. 1995 , 17, 191-7	12
2207	Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. 1995 , 18, 471-8	33
2206	Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. 1995 , 16, 271-9	42
2205	Bispecific monoclonal antibody therapy of B-cell malignancy. 1995 , 16, 199-207	17
2204	Epstein-Barr virus infection abrogates the stimulatory capacity of B cells to a major histocompatibility complex class-II-restricted proliferative T-cell clone. 1995 , 42, 137-44	8
2203	Strategies to enhance the graft-versus-malignancy effect in allogeneic transplants. 1995 , 770, 203-12	1
2202	Stem cell transplantation in acute leukemia. 1995 , 770, 262-87	4
2201	Immunological Adverse Effects of Interferon Treatment. 1995 , 4, 361-375	9
2200	Cord blood natural killer cells are functionally and phenotypically immature but readily respond to interleukin-2 and interleukin-12. 1995 , 15, 527-36	55
2199	BONE MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES AND CANCER. 1996 , 16, 393-427	3

2198	Ex vivo manipulation of cell subsets for cell therapies. 1996 , 20, 396-402	3
2197	Is cancer dangerous to the immune system?. 1996 , 8, 271-80	231
2196	Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. 1996 , 348, 1242-3	74
2195	Graft-versus-myeloma effect in two cases. 1996 , 347, 800-1	206
2194	Allogeneic bone marrow transplantation after fractionated total body irradiation in children with acute leukemia - preliminary clinical results. 1996 , 1, 29-33	
2193	Peripheral blood stem cell collection from healthy donors for allogeneic transplantation. 1996 , 17, 423-31	
2192	Acute Leukaemia. 1996 , 6, 238-249	1
2191	The immunobiology of T cell therapies for leukemias. 1996 , 96, 189-213	17
2190	Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma. 1996 , 14, 378-91	9
2189	Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis. 1996 , 106, 345-51	37
2188	Interleukin 2 in the management of acute leukaemia. 1996 , 92, 1-8	14
2187	An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. European Group for Blood and Marrow Transplantation. 1995 , 13 Suppl 2, 122-5	4
2186	Abrupt cessation of immunosuppression in a patient with persistent acute lymphoblastic leukaemia following allogeneic transplantation. 1996 , 18, 45-6	19
2185	Failure of cyclosporine to induce graft-vs-host disease or graft-vs-leukemia after syngeneic bone marrow transplantation in mice. 1996 , 20, 941-6	3
2184	Treatment and prognostic factors in acute myeloid leukaemia. 1996 , 9, 87-105	17
2183	Allogeneic bone marrow transplantation in multiple myeloma. 1996 , 92, 251-4	17
2182	The history of bone-marrow transplantation. 1996 , 10, 215-9	18
2181	Adoptive immunotherapy post bone-marrow transplantation. 1996 , 10, 237-41	6

2180	Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. 1996 , 93, 412-20	52
2179	Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. 1996 , 93, 606-12	42
2178	Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor-prognosis myelodysplastic syndrome. 1996 , 94, 507-9	10
2177	The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. 1996 , 23, 1-9	13
2176	Graft-versus-leukemia effect and its clinical implications. 1996 , 23, 477-92	12
2175	Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances. 1997 , 36, 549-64	41
2174	The allogeneic CD4+ T-cell-mediated graft-versus-leukemia effect. 1997 , 28, 33-42	14
2173	Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. 1997 , 15, 433-44	1086
2172	The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. 1997 , 25, 469-78	40
2171	Understanding the Graft-Versus-Leukaemia Reaction. 1997 , 2, 193-201	1
2170	The first clinical pilot study of roquinimex (Linomide) in cancer patients with special focus on immunological effects. 1997 , 15, 204-11	19
2169	Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. 1997 , 8, 615-24	74
2168	Graft T-cell depletion as a prerequisite for the modulation of alloreactivity after haematopoietic stem cell transplantation. 1997 , 18, 327-36	1
2167	Induction of autocytotoxic T cells with cyclosporine and interferon-gamma for patients with non-Hodgkin's lymphoma after transplantation of peripheral blood stem cells. 1997 , 100, S65-9	3
2166	Eradication of minimal residual disease during graft-versus-host reaction induced by abrupt discontinuation of immunosuppression following bone marrow transplantation in a patient with Ph1-ALL. 1997 , 10, 328-30	
2165	Influence of graft versus host reaction on the T cell repertoire differentiating from bone marrow precursors following allogeneic bone marrow transplantation. 1997 , 5, 75-82	5
2164	[Modulation of alloreactivity using genetically modified T lymphocytes]. 1997 , 4, 275-80	
2163	HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. 1997 , 276, 1719-24	1031

2162	Suppression of human hepatoma in mice through adoptive transfer of immunity to the hepatitis B surface antigen. 1997 , 27, 170-5		20
2161	Immunotherapy With Interleukin 2 After Bone Marrow Trnsplantation (BMT). 1997 , 17, 66-71		1
2160	Minor histocompatibility antigens: from T cell recognition to peptide identification. 1997 , 54, 8-14		17
2159	Allogeneic transplantation with CD34+-selected cells. 1997 , 25, 145-51		2
2158	Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy. <i>Blood</i> , 1997 , 89, 4531-4536	2.2	1001
2157	Regulation of a Graft-Versus-Leukemia Effect by Major Histocompatibility Complex Class II Molecules on Leukemia Cells: HLA-DR1 Expression Renders K562 Cell Tumors Resistant to Adoptively Transferred Lymphocytes in Severe Combined Immunodeficiency Mice/Nonobese Diabetic Mice. <i>Blood</i> , 1997 , 89, 4553-4558	2.2	9
2156	Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant. <i>Blood</i> , 1997 , 89, 3864-3872	2.2	180
2155	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997 , 89, 3880-3887	2.2	117
2154	Prevention of Graft-Versus-Host Disease in Mice Using a Suicide Gene Expressed in T Lymphocytes. <i>Blood</i> , 1997 , 89, 4636-4645	2.2	81
2153	Autologous Transplantation Therapy for Chronic Myelogenous Leukemia. <i>Blood</i> , 1997 , 89, 2623-2634	2.2	44
2152	CD6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia in First Complete Remission. <i>Blood</i> , 1997 , 89, 3039-3047	2.2	78
2151	The Role of B7 Costimulation by Murine Acute Myeloid Leukemia in the Generation and Function of a CD8+ T-Cell Line With Potent In Vivo Graft-Versus-Leukemia Properties. <i>Blood</i> , 1997 , 89, 3477-3485	2.2	58
2150	Fifty Years of Studies of the Biology and Therapy of Childhood Leukemia. <i>Blood</i> , 1997 , 90, 4243-4251	2.2	144
2149	Interleukin-12 Preserves the Graft-Versus-Leukemia Effect of Allogeneic CD8 T Cells While Inhibiting CD4-Dependent Graft-Versus-Host Disease in Mice. <i>Blood</i> , 1997 , 90, 4651-4660	2.2	85
2148	Functional Expression of Fas (CD95) in Acute Myeloid Leukemia Cells in the Context of CD34 and CD38 Expression: Possible Correlation With Sensitivity to Chemotherapy. <i>Blood</i> , 1997 , 90, 4901-4909	2.2	49
2147	HLA Class II Restricted T-Cell Reactivity to a Developmentally Regulated Antigen Shared by Leukemic Cells and CD34+ Early Progenitor Cells. <i>Blood</i> , 1997 , 90, 1083-1090	2.2	33
2146	Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect. <i>Blood</i> , 1997 , 90, 1694-1700	2.2	59
2145	Autologous Versus Unrelated Donor Allogeneic Marrow Transplantation for Acute Lymphoblastic Leukemia. <i>Blood</i> , 1997 , 90, 2962-2968	2.2	78

2144	CD34 positive blood cells for allogeneic progenitor and stem cell transplantation. 1997 , 26, 451-65	4
2143	Eradication of minimal residual disease during graft-versus-host reaction induced by abrupt discontinuation of immunosuppression following bone marrow transplantation in a patient with Ph1-ALL. 1997 , 10, 328-330	5
2142	Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. 1997 , 157, 223-30	61
2141	Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). 1997 , 11, 420-4	53
2140	Hematopoietic stem cell transplants from unrelated donors. 1997 , 157, 141-51	94
2139	Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). 1997 , 19, 577-600	57
2138	Effects of non-major histocompatibility antigens on acute graft-versus-host reaction after allogeneic bone marrow transplantation. 1997 , 20, 297-304	7
2137	Graft-versus-leukaemia. 1997 , 10, 337-55	21
2136	Donor leukocyte infusions. 1997 , 10, 357-67	20
2135	[Transplantation of hematopoietic stem cells. I: Definitions, principle indications, complications]. 1997 , 92, 480-91, 505	4
2134	Bone marrow transplantation using unrelated donors for haematological malignancies. 1997 , 14, 11-22	18
2133	Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. 1997 , 74, 1-6	95
2132	Myeloid leukemia and myelodysplastic syndrome relapsing as granulocytic sarcoma (chloroma) after allogeneic bone marrow transplantation. 1997 , 75, 239-41	39
2131	Mechanisms of the graft-versus-leukemia reaction. 1997 , 15, 248-58	80
2130	Hematopoietic transplantation: state of the art. 1997 , 15 Suppl 1, 151-7; discussion 158	13
2129	Stem cell manipulation: why and how performing peripheral blood progenitor cell purging. 1997 , 26, 101-15	7
2128	Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy. 1997 , 99, 23-9	6
2127	Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells. 1997 , 96, 147-57	29

2126	Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice. 1997 , 96, 757-61	42
2125	Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. 1997 , 20, 215-23	74
2124	Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. 1997 , 71, 59-63	61
2123	Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. 1998 , 74 Suppl 2, 321-9	60
2122	Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. 1998 , 21, 553-60	29
2121	Donor leukocyte infusion after allogeneic bone marrow transplantation was not effective for relapsed rhabdomyosarcoma. 1998 , 21, 725-6	7
2120	Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation. 1998 , 21, 801-7	5
2119	Cyclosporin A-induced graft-versus-host disease following autologous bone marrow and stem cell transplantation in hematological malignancies of childhood. 1998 , 21, 901-7	6
2118	Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. 1998 , 21, 879-85	8
2117	Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. 1998 , 21, 1055-61	61
2116	CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. 1998 , 21, 1177-81	32
2115	Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma. 1998 , 22, 185-91	3
2114	Acute graft-versus-host disease after bone marrow transplantation with a single HLA-DPB1*1001 mismatch: involvement of different TCRBV subsets. 1998 , 22, 385-92	23
2113	Double allogeneic peripheral stem cell transplants for patients at high risk of relapse. 1998 , 22, 321-4	5
2112	Negative selection and protection of normal progenitor cells for autografting. 1998 , 22, 423-30	7
2111	Autologous reconstitution with BCR-ABL-negative haematopoiesis after T cell-depleted allogeneic BMT for CML. 1998 , 22, 599-601	5
2110	Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study. 1998 , 22, 743-50	15
2109	Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. 1998 , 22, 755-61	146

2108	Graft-versus-myeloma. 1998 , 22, 835-43	68
2107	CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. 1998 , 22, 947-55	12
2106	Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. 1998 , 22, 1057-63	62
2105	A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. 1998 , 5, 1195-203	92
2104	Pharmacodynamic aspects of peptide administration biological response modifiers. 1998 , 33, 241-252	41
2103	Interleukin 2 in the treatment of acute leukemia. 1998 , 22, 1165-70	11
2102	Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. 1998 , 102, 860-71	85
2101	Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. 1998 , 28, 193-200	98
2100	Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. 1998 , 28, 90-103	69
2099	Graft-versus-host disease following second syngeneic stem cell transplantation for relapsed chronic myeloid leukemia. 1998 , 77, 283-6	6
2098	Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. 1998 , 100, 198-206	51
2097	Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. 1998 , 101, 565-70	63
2096	The role of repeat transplantation of haemopoietic stem cells and adoptive immunotherapy in treatment of leukaemia relapsing following allogeneic transplantation. 1998 , 102, 633-8	16
2095	Reconstitution of immune systems in RAG2-/- mice by transfer with interleukin-12-induced splenic hematopoietic progenitor cells. 1998 , 62, 165-70	1
2094	Related donor bone marrow transplantation for chronic myelogenous leukemia. 1998 , 12, 81-92	7
2093	Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia. 1998 , 12, 123-50	7
2092	Autologous transplantation for the treatment of chronic myelogenous leukemia. 1998 , 12, 151-72	12
2091	Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. 1998 , 29, 301-13	44

2090 Hematopoietic Stem Cell Transplantation. **1998**, 1062-1070

2089	Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma. 1998 , 9 Suppl 1, S31-9	9
2088	Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. 1998 , 339, 1177-85	465
2087	Outcomes among 562 recipients of placental-blood transplants from unrelated donors. 1998 , 339, 1565-77	1175
2086	A closed culture system for the ex vivo transduction and expansion of human T lymphocytes. 1998 , 7, 205-15	29
2085	Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor. 1998 , 9, 2049-62	36
2084	Adoptive immunotherapy following allogeneic bone marrow transplantation. 1998 , 49, 329-40	42
2083	Retrovirus-mediated transfer of the herpes simplex type I thymidine kinase gene in alloreactive T lymphocytes. 1998 , 9, 73-80	23
2082	A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. 1998 , 31, 343-9	46
2081	Recurrent breast relapses in a patient with acute lymphoblastic leukaemia following allogeneic bone marrow transplantation. 1998 , 99, 95-7	13
2080	T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. 1998 , 95, 10152-7	82
2079	Gene transfer and the treatment of childhood cancer. 1998 , 16, 269-78	2
2078	Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation. 1998 , 21, 447-53	25
2077	Chronic myelogenous leukemia: extending the prospects for cure. 1998 , 33, 137-40, 145-8, 151-2	
2076	Manipulating the Immunologic Characteristics of Both Graft and Host to Improve Transplant Outcome. 1998 , 5, 385-393	1
2075	Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. 1998 , 31, 545-50	19
2074	The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia. 1998 , 31, 317-23	4
2073	Cytotoxic T-Lymphocyte-Defined Human Minor Histocompatibility Antigens With a Restricted Tissue Distribution. <i>Blood</i> , 1998 , 91, 2197-2207	2.2 195

2072	Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection. <i>Blood</i> , 1998 , 92, 4581-4590	2.2	175
2071	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. <i>Blood</i> , 1998 , 91, 3671-3680	2.2	273
2070	Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoablation for the Treatment of Malignant and Nonmalignant Hematologic Diseases. <i>Blood</i> , 1998 , 91, 756-763	2.2	1780
2069	Bone Marrow Transplantation for Children Less Than 2 Years of Age With Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Blood</i> , 1998 , 92, 3546-3556	2.2	48
2068	Autologous Stem Cell Transplantation in Acute Myelocytic Leukemia. <i>Blood</i> , 1998 , 92, 1073-1090	2.2	104
2067	Expansion of Philadelphia Chromosome-Negative CD3+CD56+ Cytotoxic Cells From Chronic Myeloid Leukemia Patients: In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease Mice. <i>Blood</i> , 1998 , 92, 3318-3327	2.2	103
2066	Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. 1999 , 10, 1293-9		109
2065	Autologous Stem Cell Transplantation. 1999 , 99-126		1
2064	Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. 1999 , 34, 185-90		46
2063	Purine analog regimens for allogeneic transplant?. 1999 , 17, 1958-60		3
2062	Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. 1999 , 17, 1234		110
2061	Depletion of Alloreactive T Cells by a Specific Anti-Interleukin-2 Receptor p55 Chain Immunotoxin Does Not Impair In Vitro Antileukemia and Antiviral Activity. <i>Blood</i> , 1999 , 93, 3550-3557	2.2	111
2060	Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1999 , 93, 2738-2747	2.2	369
2059	Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. <i>Blood</i> , 1999 , 94, 1201-1208	2.2	243
2058	Granulocyte Colony-Stimulating Factor-Mobilized Allogeneic Stem Cell Transplantation Maintains Graft-Versus-Leukemia Effects Through a Perforin-Dependent Pathway While Preventing Graft-Versus-Host Disease. <i>Blood</i> , 1999 , 93, 4071-4078	2.2	98
2057	Feasibility of Immunotherapy of Relapsed Leukemia With Ex Vivo-Generated Cytotoxic T Lymphocytes Specific for Hematopoietic System-Restricted Minor Histocompatibility Antigens. <i>Blood</i> , 1999 , 93, 2336-2341	2.2	246
2056	Peripheral Blood Stem Cell Transplantation From Unrelated Donors: A Comparison With Marrow Transplantation. <i>Blood</i> , 1999 , 94, 455-464	2.2	169
2055	Tumor vaccines--application to childhood cancer. 1999 , 211, 336-46		2

2054	Transplantation of anergic histoincompatible bone marrow allografts. 1999 , 340, 1704-14	384
2053	Thalidomide does not interfere with graft-versus-leukemia reactivity in mice. 1999 , 5, 179-183	
2052	A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. 1999 , 189, 301-8	194
2051	CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. 1999 , 96, 8639-44	189
2050	The graft-versus-leukemia effects of allogeneic cell therapy. 1999 , 50, 369-86	104
2049	From autoimmunity to stem cell transplantation. 1999 , 30, 159-72	5
2048	Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up. 1999 , 13, 512-9	14
2047	Graft-vs.-malignancy with allogeneic blood stem cell transplantation: a potential primary treatment modality. 1999 , 3 Suppl 1, 52-8	9
2046	Post-transplant immunotherapy designed to prevent cancer recurrence. 1999 , 3 Suppl 1, 96-101	
2045	Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation?. 1999 , 20, 172-6	33
2044	Immunotherapy with CTLs restricted by nonself MHC. 1999 , 20, 180-3	62
2043	Management of relapsed acute myeloid leukaemia. 1999 , 106, 851-9	34
2042	Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. 1999 , 107, 169-75	51
2041	Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. 1999 , 107, 396-400	33
2040	Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. 1999 , 5, 839-42	232
2039	A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. 1999 , 105, 303-312	8
2038	Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. 1999 , 90, 1117-29	48
2037	Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. 1999 , 13, 2079-86	109

2036	Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. 1999 , 23, 145-50	19
2035	The cytotoxicity of mafosfamide on G-CSF mobilized hematopoietic progenitors is reduced by SH groups of albumin--implications for further purging strategies. 1999 , 23, 157-61	2
2034	Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse. 1999 , 23, 475-82	20
2033	Rapid tapering of cyclosporin to maximise the graft-versus-leukaemia effect. 1999 , 23, 632-3	2
2032	Successful one antigen mismatched bone marrow transplant for chronic myeloid leukemia (CML) after two failed syngeneic transplants. 1999 , 23, 1085-6	2
2031	Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation. 1999 , 23, 1153-9	30
2030	Donor lymphocyte infusion induced molecular remission in relapse of acute myeloid leukaemia after allogeneic bone marrow transplantation. 1999 , 23, 1201-3	14
2029	Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin. 1999 , 23, 1139-43	31
2028	Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. 1999 , 23, 1217-22	16
2027	Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients. 1999 , 24, 29-34	15
2026	A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes. 1999 , 24, 129-37	13
2025	Unrelated donor stem cell transplantation after autologous transplantation: experience of a single center. 1999 , 24, 279-82	5
2024	Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. 1999 , 24, 629-35	45
2023	HLA-identical sibling peripheral blood progenitor cell transplants (PBPCT). 1999 , 24, 707-14	2
2022	Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. 1999 , 24, 925-7	24
2021	Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion. 1999 , 24, 1073-7	2
2020	Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex. 1999 , 24, 1057-63	9
2019	Adoptiver Transfer von malignomreaktiven T-Zellen. 1999 , 5, 688	1

2018	T cell-based immunotherapy for cancer: a virtual reality?. 1999 , 49, 74-100, 65	9
2017	Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models. 1999 , 27, 461-9	13
2016	Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice. 1999 , 27, 1503-10	43
2015	Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. 1999 , 27, 1519-27	25
2014	Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases. 1999 , 14, 45-9	6
2013	A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. 1999 , 85, 1506-1513	48
2012	Cell Separation. 1999 , 215-243	1
2011	Use of interleukin-2 in the management of haematological malignancies: focus on minimal residual disease. 1999 , 12, 43-53	2
2010	Prevention of graft versus host disease by inactivation of host antigen-presenting cells. 1999 , 285, 412-5	1043
2009	Potential of gene therapy in bone marrow transplantation. 1999 , 11, 1-6	
2008	Immunological defects after suicide gene therapy of experimental graft-versus-host disease. 1999 , 10, 2701-7	14
2007	Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. 1999 , 5, 123-32	53
2006	IMMUNOTHERAPY IN PEDIATRIC ONCOLOGY. 1999 , 19, 309-326	
2005	Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. 1999 , 13, 1041-57, vii-viii	38
2004	T-cell depletion of allogeneic peripheral blood stem cells. 1999 , 12, 87-98	2
2003	Normal and leukaemic haematopoiesis in bone marrow and peripheral blood of patients with chronic myeloid leukaemia. 1999 , 12, 199-208	2
2002	Suicide gene-mediated modulation of graft-versus-host disease. 1999 , 34, 473-80	24
2001	Predicting costs of stem-cell transplantation. 2000 , 18, 64-71	88

2000	New Developments in the Therapy of Acute Myelocytic Leukemia. 2000 , 69-89	17
1999	Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. 2000 , 111, 745-753	23
1998	The BCR-ABL Oncoprotein and Immunological Targeting - Vaccination for Tumor Prevention and Therapy. 2000 ,	
1997	Nonmyeloablative hematopoietic stem cell allografting. 2000 , 5, 366-371	2
1996	Immunotherapy for malignancies and viral infections. 2000 , 5, 197-202	2
1995	Estimation of current leukaemia-free survival following donor lymphocyte infusion therapy for patients with leukaemia who relapse after allografting: application of a multistate model. 2000 , 19, 3005-16	31
1994	Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. 2000 , 40, 468-76	23
1993	Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Soci� Fran�aise de Greffe de moelle (SFGM). 2000 , 108, 400-7	119
1992	Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). 2000 , 109, 644-51	59
1991	Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?. 2000 , 110, 12-7	23
1990	New strategies for bone marrow transplantation. 2000 , 12, 542-51	38
1989	Is it time to reduce toxicity by non-myeloablative conditioning for allogeneic stem cell transplantation in children?. 2000 , 4, 247-51	3
1988	The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). 2000 , 25, 1053-8	27
1987	Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. 2000 , 25, 1121-7	8
1986	Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. 2000 , 26, 1-16	34
1985	High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. 2000 , 26, 147-52	41
1984	High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. 2000 , 26, 251-5	93
1983	Donor leukocyte infusions in acute lymphocytic leukemia. 2000 , 26, 511-6	185

1982	Significant MLR but not CTL responses against recipient antigens generated in T cells from bone marrow chimeras recovered from acute GVHD. 2000 , 26, 1069-76	9
1981	Donor leukocyte infusions for multiple myeloma. 2000 , 26, 1179-84	146
1980	Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia. 2000 , 26, 1251-4	21
1979	Using peripheral blood progenitor cells (PBPC) for transplantation in pediatric patients: a state-of-the-art review. 2000 , 26, 1291-8	20
1978	Allogeneic stem cell transplantation in a patient with refractory Burkitt's lymphoma using non-myeloablative conditioning regimen. 2000 , 26, 1351-4	14
1977	Transplantation of syngenic bone marrow contaminated with NGFr-marked WEHI-3B cells: an improved model of leukemia relapse in mice. 2000 , 14, 457-65	6
1976	Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD. 2000 , 25, 13-8	45
1975	Decreased graft-versus-host disease after haplotype mismatched bone marrow allografts in miniature swine following interleukin-2 treatment. 2000 , 25, 47-52	10
1974	Successful treatment of relapsed CML after cord blood transplantation with donor leukocyte infusion IL-2 and IFNalpha. 2000 , 25, 219-22	11
1973	The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models. 2000 , 25, 263-6	8
1972	Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide. 2000 , 25, 489-94	18
1971	Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. 2000 , 25, 623-32	56
1970	Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting. 2000 , 25, 1059-65	44
1969	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. 2000 , 111, 18-29	1
1968	CHRONIC MYELOGENOUS LEUKAEMIA. 2000 , 111, 993-1009	3
1967	Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. 2000 , 111, 708-710	
1966	Non-myeloablative stem cell transplants. 2000 , 111, 6-17	0
1965	Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. 2000 , 111, 766-773	

1964	Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. 2000 , 111, 745-753		1
1963	Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. 2000 , 111, 1130-1137		0
1962	Transplantation of IL-2-transduced murine bone marrow is associated with dose-dependent toxicity. 2000 , 28, 895-906		
1961	Ex vivo T lymphocyte expansion for retroviral transduction: influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution. 2000 , 28, 1137-46		20
1960	Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation. 2000 , 28, 1225-31		18
1959	Adoptive allogeneic immunotherapy--history and future perspectives. 2000 , 23, 133-50		16
1958	T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999. 2000 , 23, 151-62		7
1957	Allogeneic bone marrow transplantation for lymphoma. 2000 , 14, 1-13		27
1956	Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. 2000 , 2, 132-9		19
1955	Biologic and clinical aspects of autologous stem cell transplantation with mobilized peripheral blood cells in chronic myelogenous leukemia. 2000 , 2, 144-51		1
1954	Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens. 2000 , 2, 182-91		5
1953	Culture requirements for induction of dendritic cell differentiation in acute myeloid leukemia. 2000 , 79, 355-62		23
1952	Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. <i>Blood</i> , 2000 , 96, 1047-1055	2.2	50
1951	Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. <i>Blood</i> , 2000 , 95, 2426-2433	2.2	61
1950	Stem Cell Transplantation for Chronic Lymphocytic Leukaemia: Is this the Way Forward in the New Millennium?; Malignancy; Current Clinical Practice. 2000 , 5, 265-273		
1949	Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome. 2000 , 18, 1856-66		44
1948	Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. <i>Blood</i> , 2000 , 95, 1572-1579	2.2	135
1947	A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. <i>Blood</i> , 2000 , 95, 3693-3701	2.2	30

1946	Bone Marrow Engraftment Analysis After Allogeneic Bone Marrow Transplantation. 2000 , 20, 197-225	55
1945	The benefits of an alloresponse: graft-versus-tumor. 2000 , 9, 347-54	11
1944	Lymphokines post autologous peripheral blood stem cell transplantation in children. 2000 , 17, 9-13	1
1943	Cancer immunotherapy with alloreactive lymphocytes. 2000 , 343, 802-3	23
1942	Evolving strategies to address adverse transplant outcomes associated with T cell depletion. 2000 , 9, 327-37	22
1941	Preservation of graft-versus-infection effects after suicide gene therapy for prevention of graft-versus-host disease. 2000 , 11, 2473-81	17
1940	Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease. 2000 , 9, 355-66	10
1939	Immunotherapy of AML: future directions. 2000 , 53, 49-54	18
1938	Targeted therapies for the myeloid leukaemias. 2000 , 9, 1197-205	12
1937	Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. 2000 , 5, 487-96	18
1936	Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice. 2000 , 165, 1634-40	35
1935	Abrogation of negative selection by GVHR induced by minor histocompatibility antigens or H-2D antigen alone. 2000 , 202, 268-79	9
1934	Human umbilical cord blood banking and transplantation: a state of the art. 2000 , 90, 13-25	35
1933	Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease. 2000 , 26, 411-27	6
1932	T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. 2000 , 6, 646-53	36
1931	Cross-protective murine graft-versus-leukemia responses to phenotypically distinct myeloid leukemia lines. 2000 , 6, 537-47	5
1930	Allogeneic bone marrow transplantation for young adult patients with newly diagnosed acute myeloid leukemia: HLA-Matched sibling donor availability does not improve treatment outcome. 2000 , 42, 119-129	3
1929	Generation of dendritic cells from human chronic myelomonocytic leukemia cells in fetal calf serum-free medium. 2000 , 38, 577-86	7

1928	From leukocyte reduction to leukocyte transfusion: the immunological effects of transfused leukocytes. 2000 , 13, 585-600	9
1927	Placental blood for bone marrow replacement: the New York Blood Center's program and clinical results. 2000 , 13, 565-84	46
1926	Induction of autologous graft-versus-host disease with cyclosporin A after peripheral blood stem cell transplantation: analysis of factors affecting induction. 2000 , 106, S51-7	12
1925	Developmental approaches in immunological control of acute myelogenous leukaemia. 2001 , 14, 189-209	2
1924	Allogeneic transplantation using non-myeloablative transplant regimens. 2001 , 14, 701-22	12
1923	The biology of natural killer cells and implications for therapy of human disease. 2001 , 10, 451-63	27
1922	The current status of T-cell depleted allogeneic stem-cell transplants in adult patients with AML. 2001 , 3, 175-88	7
1921	Transgenic interleukin 2 secreted by CML dendritic cells stimulates autologous T(H)1 T cells. 2001 , 3, 97-105	3
1920	Immune reconstitution after autologous hematopoietic stem cell transplantation. 2001 , 76, 407-12	24
1919	Antibody-directed, effector cell-mediated tumor destruction. 2001 , 15, 703-21	32
1918	Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. 2001 , 15, 97-120	21
1917	The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. 2001 , 7, 31-8	45
1916	Infusion of select leukemia-reactive TCR Vbeta+ T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation. 2001 , 7, 187-96	25
1915	Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. 2001 , 7, 230-8	38
1914	Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. 2001 , 7, 620-30	56
1913	Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches. 2001 , 7, 656-64	29
1912	Immunotherapy of cancer with alloreactive lymphocytes. 2001 , 2, 491-8	34
1911	Evolution of bone marrow transplantation--the original immunotherapy. 2001 , 22, 88-92	18

1910	Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen. 2001 , 7, 352-8		33
1909	An allogeneic anti-cancer effect after hematopoietic stem cell transplantation. 2001 , 33, 1862-4		3
1908	Extending the role of allogeneic stem-cell transplantation. 2001 , 357, 652-4		8
1907	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001 , 97, 3390-400	2.2	1183
1906	Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group. 2001 , 42, 57-65		9
1905	Prevention of acute graft-versus-host-disease by selective depletion of T cells reactive with minor histocompatibility antigens on epithelial cells. 2001 , 40, 385-91		2
1904	Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. <i>Blood</i> , 2001 , 98, 2043-51	2.2	546
1903	Mafofamide-Purged Peripheral Blood Stem Cell Harvest: Case Report of a 54-Year-Old Patient with Relapsed Acute Myeloid Leukemia. 2001 , 28, 161-164		
1902	Immunotherapy of acute myeloid leukemia. 2001 , 2, 209-15		4
1901	Non-myeloablative transplants for malignant disease. 2001 , 2001, 375-91		80
1900	Transplante de medula 6sea e transplante de sangue de cord6o umbilical em pediatria. 2001 , 77, 345		3
1899	No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. 2001 , 19, 3406-14		81
1898	A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. 2001 , 71, 1131-7		14
1897	Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation. 2001 , 76, 407-412		68
1896	Reducing transplant toxicity. 2001 , 8, 342-8		10
1895	Transforming growth factor-beta inhibits lymphokine activated killer cytotoxicity of bone marrow cells: implications for the graft-versus-leukemia effect in irradiation allogeneic bone marrow chimeras. 2001 , 71, 292-9		27
1894	Transplantation of Haematopoietic Stem Cells. 2001 ,		
1893	Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. <i>Blood</i> , 2001 , 98, 3359-66	2.2	51

1892	Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease. <i>Blood</i> , 2001 , 98, 3367-75	2.2	41
1891	Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. <i>Blood</i> , 2001 , 98, 565-72	2.2	148
1890	Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. <i>Blood</i> , 2001 , 97, 63-72	2.2	245
1889	Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. <i>Blood</i> , 2001 , 97, 2948-56	2.2	119
1888	Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. <i>Blood</i> , 2001 , 97, 3138-45	2.2	42
1887	In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. <i>Blood</i> , 2001 , 97, 1474-82	2.2	47
1886	Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. <i>Blood</i> , 2001 , 98, 3186-91	2.2	154
1885	CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. <i>Blood</i> , 2001 , 98, 3221-7	2.2	208
1884	Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. <i>Blood</i> , 2001 , 98, 579-85	2.2	222
1883	T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. <i>Blood</i> , 2001 , 98, 934-9	2.2	174
1882	Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. <i>Blood</i> , 2001 , 98, 1695-700	2.2	179
1881	No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. <i>Blood</i> , 2001 , 98, 1739-45	2.2	99
1880	The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. <i>Blood</i> , 2001 , 98, 1982-4	2.2	78
1879	Suicide gene therapy of graft-versus-host disease: immune reconstitution with transplanted mature T cells. <i>Blood</i> , 2001 , 98, 2071-6	2.2	22
1878	Treatment of Relapsing Ph+ Acute Lymphoblastic Leukemia with Donor Leukocyte Infusion Followed by Quantitative Monitoring of Residual Disease. 2001 , 6, 261-5		4
1877	A decade of progress in allogeneic hematopoietic cell transplantation: 1990-2000. 2001 , 81, 1-59		1
1876	Current Treatment of Chronic Myeloid Leukemia. 2001 , 6, 1-17		
1875	Nonmyeloablative hematopoietic cell transplantation. 2001 , 13, 95-100		23

1874	Bone marrow transplant conditioning intensified with liposomal clodronate to eliminate residual host antigen presenting cells fails to ameliorate GVHD and increases PERI-BMT mortality. 2001 , 71, 611-8	7
1873	Research opportunities in transfusion medicine. 2001 , 285, 577-80	3
1872	[Cutaneous manifestations of graft-versus-host disease]. 2001 , 96, 457-66	4
1871	Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 2001 , 80, 267-71	2
1870	Allogeneic stem-cell transplantation in renal-cell carcinoma. 2001 , 3, 433-7	3
1869	Cord blood transplantation from HLA-mismatched unrelated donors as a treatment for children with haematological malignancies. 2001 , 112, 981-7	27
1868	Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation. 2001 , 114, 31-5	8
1867	Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. 2001 , 114, 11-24	44
1866	Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. 2001 , 115, 95-104	56
1865	Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. 2001 , 114, 544-50	20
1864	Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. 2001 , 115, 622-9	61
1863	Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. 2001 , 115, 653-9	89
1862	Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. 2001 , 115, 935-44	52
1861	Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia. 2001 , 126, 403-11	58
1860	Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation. 2001 , 31, 15-22	23
1859	Novel approaches to transplant conditioning. 2001 , 19, 43-57	1
1858	Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. 2001 , 16, 82-7	7
1857	The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2001 , 98, 3192-204	2.2 342

1856	Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. 2001 , 7, 789-94	155
1855	Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. 2001 , 27 Suppl 2, S13-22	26
1854	TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. 2001 , 27, 1087-93	45
1853	Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation. 2001 , 28, 157-61	26
1852	Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. 2001 , 28, 243-9	69
1851	Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. 2001 , 28, 335-9	29
1850	Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. 2001 , 28, 865-71	68
1849	Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. 2001 , 28, 951-6	43
1848	A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. 2001 , 28, 1161-6	25
1847	Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. 2001 , 15, 246-55	61
1846	Prospect for immunotherapy of acute lymphoblastic leukemia. 2001 , 15, 701-6	10
1845	Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. 2001 , 15, 1339-46	44
1844	An optimised biphasic culture system for the generation of functional dendritic cells from patients with acute lymphoblastic leukaemia at presentation and in clinical remission. 2001 , 15, 1596-603	10
1843	Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. 2001 , 15, 1976-85	103
1842	Haematopoietic cell transplantation as immunotherapy. 2001 , 411, 385-9	341
1841	Allogeneic stem cell transplantation as salvage therapy for patients relapsing after autologous transplantation: experience from a single institution. 2001 , 25, 379-84	5
1840	Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders. 2001 , 5, 135-46	26
1839	Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. 2001 , 29, 458-70	76

1838	Identification of T-cell clones showing expansion associated with graft-vs-leukemia effect on chronic myelogenous leukemia in vivo and in vitro. 2001 , 29, 471-6	16
1837	An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. 2001 , 66, 50-6	13
1836	The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. 2001 , 193, 195-206	160
1835	Acute Leukemias VIII. 2001 ,	1
1834	Chronic myelogenous leukemia. 2001 , 2001, 87-112	65
1833	High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. 2001 , 6, 247-56	28
1832	Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. 2001 , 27, 601-6	76
1831	Acute myeloid leukemia. 2001 , 2001, 62-86	90
1830	CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. 2001 , 98, 7492-7	86
1829	Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. 2001 , 166, 4818-21	41
1828	Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. <i>Blood</i> , 2001 , 97, 2962-71	2.2 652
1827	The predictive value of helper T lymphocyte precursor frequencies for graft-versus-host disease and graft-versus-leukaemia effects in allogeneic bone marrow transplantation. 2001 , 27, 949-58	10
1826	A systematic overview of chemotherapy effects in acute myeloid leukaemia. 2001 , 40, 231-52	48
1825	Transplantation Surgery. 2001 ,	7
1824	Novel approaches to allogeneic stem cell therapy. 2001 , 1, 3-15	9
1823	Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients. 2001 , 27, 999-1005	6
1822	A Systematic Overview of Chemotherapy Effects in Acute Myeloid Leukaemia. 2001 , 40, 231-252	51
1821	The graft-versus-tumor potential of allogeneic cell therapy: an update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation. 2001 , 10, 465-80	11

1820	Nonmyeloablative allogeneic hematopoietic stem cell transplantation. 2002 , 11, 243-63	13
1819	Role of dendritic cells in graft-versus-host disease. 2002 , 11, 601-16	12
1818	Immunology for Surgeons. 2002 ,	
1817	Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells. 2002 , 11, 301-14	18
1816	The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. 2002 , 8, 441-448	39
1815	The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. 2002 , 196, 359-68	80
1814	Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. 2002 , 13, 979-88	33
1813	Effect of combined cytostatic cyclosporin A and cytolytic suicide gene therapy on the prevention of experimental graft-versus-host disease. 2002 , 9, 201-7	7
1812	Separating graft-versus-tumor from graft-versus-host reactions. 2002 , 43, 725-33	7
1811	Treatment of lymphoid malignancies with non-myeloablative stem cell transplantation. 2002 , 7, 151-5	1
1810	Recovery of lymphocyte and dendritic cell subsets following reduced intensity allogeneic bone marrow transplantation. 2002 , 7, 157-64	29
1809	Allogeneic hematopoietic stem cell transplantation: complications and results. 2002 , 162, 1558-66	127
1808	A graft-versus-tumor effect in a patient with ependymoma who received an allogeneic bone marrow transplant for therapy-related leukemia. Case report. 2002 , 97, 474-6	7
1807	Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. 2002 , 138, 1359-65	53
1806	[Dose-reduced conditioning before allogeneic stem cell transplantation: principles, clinical protocols and preliminary results]. 2002 , 127, 2186-92	5
1805	Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children. 2002 , 29, 497-502	51
1804	Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?. 2002 , 29, 853-9	34
1803	Influence of tumor vaccines on graft versus tumor activity and graft versus host disease in allogeneic bone marrow transplantation. 2002 , 43, 503-10	7

1802	Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation. 2002 , 43, 9-17		10
1801	Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. 2002 , 29, 391-7		70
1800	The role of mini-allotransplants in the treatment of solid tumors. 2002 , 13 Suppl 4, 281-6		
1799	Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. 2002 , 20, 4324-30		60
1798	October 2002. 2002 , 138, 1338		
1797	CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. 2002 , 196, 401-6		584
1796	Retrospective comparison of CD34-selected allogeneic peripheral blood stem cell transplantation followed by CD8-depleted donor lymphocyte infusions with unmanipulated bone marrow transplantation. 2002 , 7, 137-43		3
1795	Bone marrow transplantation for multiple myeloma: where we are today. 2002 , 14, 147-51		4
1794	Nonmyeloablative hematopoietic transplantation for treatment of malignant diseases. 2002 , 7, 275-278		2
1793	Minor histocompatibility antigens: molecular targets for adoptive cellular immunotherapy. 2002 , 7, 299-304		4
1792	Reduced-intensity allogeneic transplantation for lymphoma. 2002 , 14, 475-83		2
1791	Leukemias. 2002 , 45, 866-78		12
1790	Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. 2002 , 8, 2-11		28
1789	Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. 2002 , 73, 1137-41		34
1788	Hematopoietic stem cell transplantation: the Vancouver experience. 2002 , 7, 145-9		
1787	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. <i>Blood</i> , 2002 , 100, 406-14	2.2	445
1786	Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. <i>Blood</i> , 2002 , 100, 3128-34	2.2	163
1785	Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?. <i>Blood</i> , 2002 , 99, 768-84	2.2	151

1784	Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. <i>Blood</i> , 2002 , 99, 3041-9	2.2	53
1783	Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. <i>Blood</i> , 2002 , 100, 1903-9	2.2	208
1782	Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. <i>Blood</i> , 2002 , 100, 547-52	2.2	56
1781	Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. <i>Blood</i> , 2002 , 100, 2020-5	2.2	24
1780	Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD. <i>Blood</i> , 2002 , 100, 2650-8	2.2	59
1779	Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. <i>Blood</i> , 2002 , 100, 2243-5	2.2	152
1778	Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. <i>Blood</i> , 2002 , 100, 1894-902	2.2	47
1777	Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. <i>Blood</i> , 2002 , 100, 3121-7	2.2	215
1776	Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. <i>Blood</i> , 2002 , 100, 3429-31	2.2	32
1775	Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. 2002 , 9, 123-37		80
1774	Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. 2002 , 20, 4655-64		129
1773	188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. 2002 , 43, 2125-31		60
1772	Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. <i>Blood</i> , 2002 , 99, 4610-7	2.2	72
1771	Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. 2002 , 8, 351-9		30
1770	Allogeneic haemopoietic stem cell transplantation for non-Hodgkin's lymphoma. 2002 , 15, 481-504		4
1769	Stem cell transplantation in adult ALL patients. 2002 , 15, 653-74		11
1768	Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. 2002 , 11, 265-76		42
1767	Main Session II. 2002 , 81, S30-S37		4

1766	Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy. 2002 , 62 Suppl 1, 79-88		8
1765	CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect. 2002 , 4, 353-63		10
1764	Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. 2002 , 4, 395-406		54
1763	Hematopoietic cellular therapy: implications for the flow cytometry laboratory. 2002 , 16, 455-76		5
1762	The choice of allogeneic or autologous hematopoietic transplantation for NHL. 2002 , 4, 259-69		1
1761	Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. 2002 , 8, 557-68		6
1760	Umbilical cord blood transplantation: where do we stand?. 2002 , 8, 637-47		21
1759	Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. 2002 , 8, 601-7		24
1758	Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. <i>Blood</i> , 2002 , 100, 1935-47	2.2	405
1757	Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats. 2002 , 13, 187-98		34
1756	Non-myeloablative stem cell transplantation for induction of host-versus-graft tolerance for adoptive immunotherapy of malignant and nonmalignant diseases and towards transplantation of organ allografts. 2002 , 34, 3371-3		3
1755	Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. 2002 , 8, 139-44		30
1754	Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA. 2002 , 8, 412-9		32
1753	Phase II study of a moderate-intensity preparative regimen with allogeneic peripheral blood stem cell transplantation for hematologic diseases: the Texas Transplant Consortium experience. 2002 , 8, 420-8		10
1752	Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. 2002 , 39, 23-31		57
1751	Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. 2002 , 39, 57-62		17
1750	Acute myelogenous leukemia: advances and limitations of treatment. 2002 , 93, 257-63		14
1749	Adoptive transfer of T-cell immunity. 2002 , 23, 264-9		29

1748	Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals. 2002 , 27, 159-66	8
1747	Immune escape mechanisms of childhood ALL and a potential countering role for DC-like leukemia cells. 2002 , 4, 165-75	10
1746	Graft versus Leukemia and Graft versus Tumor Activity. 2002 , 325-338	
1745	T-cell therapy of leukemia. 2002 , 9, 114-22	30
1744	Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. 2002 , 20, 405-12	207
1743	Critical factors in optimizing graft-versus-leukemia effect for relapsed leukemias. 2002 , 20, 2756; author reply 2756-7	3
1742	Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. 2002 , 30, 89-96	26
1741	Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning. 2002 , 30, 1346-53	24
1740	Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. 2002 , 94, 2409-15	99
1739	Analysis of the clonal expansion of TCR V β cells in patients with CML after DLI. 2002 , 1, 145-148	
1738	Hematopoietic cell transplantation as a form of immunotherapy. 2002 , 75, 222-7	8
1737	Suicide-gene-Transduced donor T-cells for controlled graft-versus-host disease and graft-versus-tumor. 2002 , 76, 305-9	6
1736	The clinical implications of mixed lymphocyte reaction with leukemic cells. 2002 , 76, 370-5	
1735	Minor histocompatibility antigens--targets of graft versus leukemia responses. 2002 , 76 Suppl 2, 155-61	28
1734	Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. 2002 , 76 Suppl 1, 184-9	20
1733	Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?. 2002 , 76 Suppl 1, 226-47	23
1732	Progress in the treatment of acute myeloid leukaemia in adults. 2002 , 76 Suppl 1, 253-8	74
1731	Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status. Results of a single-center study of 24 patients. 2002 , 81, 582-7	7

1730	Transplantation von Knochenmark und peripheren Blutstammzellen. 2002 , 16, 1-1	
1729	Feasibility of using genetic linkage analysis to identify the genes encoding T cell-defined minor histocompatibility antigens. 2002 , 59, 293-303	25
1728	Induction of a transient graft vs. leukemia effect following unrelated cord blood transplantation. 2002 , 6, 348-51	6
1727	Unusual presentation of central nervous system relapse with oculomotor nerve palsy in a case of CD56-positive acute myeloid leukemia following allogeneic stem cell transplantation. 2002 , 6, 260-5	5
1726	Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. 2002 , 116, 299-307	20
1725	Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B-lineage acute lymphoblastic leukaemia in first or second remission. 2002 , 117, 109-18	14
1724	Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. 2002 , 117, 821-7	94
1723	Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. 2002 , 118, 108-16	32
1722	An association between human leucocyte antigen alleles and acute and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. 2002 , 119, 751-9	15
1721	Cellular therapy for haematological malignancies. 2002 , 83, 294-304	1
1720	Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. 2002 , 30, 95-102	62
1719	Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience. 2002 , 30, 651-9	12
1718	Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?. 2002 , 30, 797-804	31
1717	The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors. 2002 , 30, 761-8	21
1716	Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma. 2002 , 30, 805-12	1
1715	Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. 2002 , 16, 1311-8	98
1714	Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. 2002 , 16, 1423-31	94
1713	Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. 2002 , 16, 2129-33	57

1712	Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. 2002 , 16, 2423-8	84
1711	History of haematopoietic stem-cell transplantation. 2002 , 2, 231-8	88
1710	Cytolytic pathways in haematopoietic stem-cell transplantation. 2002 , 2, 273-81	138
1709	T-cell-receptor gene therapy. 2002 , 2, 512-9	210
1708	Autologous stem cell transplantation in acute lymphocytic leukemia. 2002 , 20, 3-10	30
1707	Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. 2002 , 22, 64-9	13
1706	Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. 2002 , 22, 70-4	26
1705	Alemtuzumab in stem cell transplantation. 2002 , 19 Suppl, S33-47	20
1704	Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors. 2003 , 41, 197-206	3
1703	Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation. 2003 , 77, 3-14	25
1702	Immunoregulatory cells for transplantation tolerance and graft-versus-leukemia effect. 2003 , 78, 188-94	7
1701	Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation. 2003 , 78, 195-207	13
1700	Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation. 2003 , 78, 208-12	18
1699	Immuntherapeutische Behandlung therapierefraktärer und rezidivierender akuter lymphatischer Leukämien im Kindes- und Jugendalter. 2003 , 151, 154-165	
1698	Neue Formen der Stammzelltransplantation. 2003 , 151, 146-153	
1697	CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells. 2003 , 31, 81-8	11
1696	Allogeneic hematopoietic stem cell transplantation--yesterday, today, and tomorrow. 2003 , 31, 1-10	91
1695	Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. 2003 , 31, 873-80	17

1694	Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. 2003 , 31, 903-10	41
1693	Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases. 2003 , 31, 934-40	4
1692	Recent advances in allogeneic hematopoietic stem-cell transplantation. 2003 , 141, 7-32	27
1691	The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. 2003 , 17, 153-62	63
1690	Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. 2003 , 46, 139-63	17
1689	Reduced-intensity allogeneic hematopoietic cell transplantation: Graft versus tumor effects with decreased toxicity. 2003 , 7, 168-78	5
1688	Risk factors for moderate-to-severe acute graft-vs.-host disease after allogeneic stem cell transplantation in children. 2003 , 7, 130-6	9
1687	Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies. 2003 , 25, 383-91	3
1686	Novel treatment for refractory acute myeloid leukemia. 2003 , 7, 422-5	
1685	Development of reduced-intensity hematopoietic stem cell transplantation in the National Cancer Center Hospital, Japan. 2003 , 7, 318-28	1
1684	A clinical role for peripheral blood lymphocyte infusions and perspectives on collection. 2003 , 7, 305-11	4
1683	Reduced-intensity stem cell transplantation in two cases of metastatic renal cell carcinoma. 2003 , 10, 610-4; discussion 615	1
1682	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. 2003 , 120, 281-8	80
1681	Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. 2003 , 121, 296-303	15
1680	Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. 2003 , 122, 788-94	38
1679	Core-binding factor-beta positive acute myeloid leukaemia cells induce T-cell responses. 2003 , 123, 819-29	5
1678	Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma. 2003 , 131, 340-6	4
1677	In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy. 2003 , 133, 467-75	8

1676	New advances in acute graft-versus-host disease prophylaxis. 2003 , 13, 387-97	8
1675	Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. 2003 , 31, 175-81	56
1674	Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. 2003 , 31, 253-61	120
1673	Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. 2003 , 31, 305-8	8
1672	Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. 2003 , 31, 387-92	64
1671	'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning. 2003 , 31, 739-46	30
1670	Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?. 2003 , 31, 953-60	12
1669	Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. 2003 , 31, 967-72	28
1668	Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. 2003 , 32, 243-50	33
1667	Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses. 2003 , 32, 495-504	16
1666	A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation. 2003 , 32, 557-61	5
1665	Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. 2003 , 32, 777-84	32
1664	Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. 2003 , 32, 881-7	43
1663	Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia. 2003 , 32, 889-95	5
1662	Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. 2003 , 17, 621-9	67
1661	Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. 2003 , 17, 869-75	113
1660	The presence and longevity of peripherally expanded donor-derived TCRalpha+ mature T lymphocyte clones after allogeneic bone marrow transplantation for adult myeloid leukemias. 2003 , 17, 1626-35	8
1659	Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. 2003 , 17, 1865-70	77

1658	Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. 2003 , 17, 2168-77	103
1657	Taming transplantation with T cells. 2003 , 9, 1117-8	5
1656	CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. 2003 , 9, 1144-50	1044
1655	Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes. 2003 , 17, 1243-60	3
1654	Future directions in the management of ovarian cancer. 2003 , 17, 1075-85	5
1653	Graft-vs.-Host Disease. 633-664	3
1652	Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. 2003 , 4, 39-45	5
1651	Alloreactive killer cells: hindrance and help for haematopoietic transplants. 2003 , 3, 108-22	139
1650	Ethical reappraisal of 15 years of cord-blood transplantation. 2003 , 361, 250-2	44
1649	Allogeneic stem cell transplantation for chronic myeloid leukemia. 2003 , 40, 59-71	44
1648	Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. 2003 , 29, 283-90	26
1647	Chronic graft-versus-host disease. 2003 , 9, 215-33	654
1646	Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. 2003 , 9, 243-56	166
1645	Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma. 2003 , 21, 79-81	1
1644	Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. 2003 , 9, 312-9	30
1643	Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. 2003 , 9, 320-9	126
1642	Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. 2003 , 9, 472-81	68
1641	Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. 2003 , 9, 170-176	56

1640	[Allogeneic adoptive immunotherapy]. 2003 , 10, 170-4		0
1639	The allogeneic effect in non-Hodgkin's lymphoma. 2003 , 44 Suppl 3, S91-7		1
1638	Depletion of host reactive T cells by photodynamic cell purging and prevention of graft versus host disease. 2003 , 44, 1871-9		10
1637	Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. 2003 , 21, 3744-53		128
1636	Allogeneic immune replacement as cancer immunotherapy. 2003 , 3, 1051-60		3
1635	Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. 2003 , 100, 1180-4		83
1634	Elimination of leukemia in the absence of lethal graft-versus-host disease after allogeneic bone marrow transplantation. 2003 , 170, 3046-53		16
1633	Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. 2003 , 21, 3060-5		55
1632	Cellular engineering of HSV-tk transduced, expanded T lymphocytes for graft-versus-host disease management. 2003 , 110, 121-31		3
1631	Adoptive immunotherapy in chimeras with donor lymphocytes. 2003 , 110, 110-20		18
1630	Leukemia vaccines. 2003 , 110, 160-70		2
1629	A 41-year-old woman with chronic myelogenous leukemia. 2003 , 290, 1083-90		
1628	The current status of hematopoietic cell transplantation. 2003 , 54, 491-512		109
1627	Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?. <i>Blood</i> , 2003 , 101, 4233-44	2.2	227
1626	Transplantation in Hematology and Oncology II. 2003 ,		
1625	Addition of a low fixed number of CD3+ cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation. 2003 , 12, 309-20		10
1624	Minor histocompatibility antigens on canine hemopoietic progenitor cells. 2003 , 170, 5861-8		24
1623	Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors. 2003 , 14, 1177-84		19

1622	The graft-versus-lymphoma effect: fact, fiction, or opportunity?. 2003 , 21, 3713-5		13
1621	New directions in natural killer cell-based immunotherapy of human cancer. 2003 , 3, 237-50		27
1620	Minitransplants: allogeneic stem cell transplantation with reduced toxicity. 2003 , 58, 37-45		1
1619	Acute lymphocytic leukemia: role of hematopoietic stem cell transplantation in current management. 2003 , 10, 463-8		5
1618	New developments in anti-tumor efficacy and malignant transformation of human natural killer cells. 2003 , 10, 55-9		5
1617	Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. 2003 , 10, 31-9		14
1616	Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy. 2003 , 26, 257-69		6
1615	Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans. 2003 , 75, 1061-6		14
1614	Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. 2003 , 76, 230-6		41
1613	Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. 2003 , 76, 1208-13		491
1612	Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. 2003 , 75, 2135-43		36
1611	New developments in allotransplant immunology. 2003 , 2003, 350-71		47
1610	Autologous Graft-vs.-Host Disease. 405-413		
1609	Hematopoietic cell transplantation for benign hematological disorders and solid tumors. 2003 , 2003, 372-97		45
1608	Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. <i>Blood</i> , 2003 , 101, 441-5	2.2	185
1607	Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. <i>Blood</i> , 2003 , 101, 469-72	2.2	42
1606	A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. <i>Blood</i> , 2003 , 101, 2476-82	2.2	132
1605	Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. <i>Blood</i> , 2003 , 101, 2877-85	2.2	60

1604	Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Blood</i> , 2003 , 102, 1108-13	2.2	95
1603	Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. <i>Blood</i> , 2003 , 102, 470-6	2.2	169
1602	The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. <i>Blood</i> , 2003 , 102, 621-9	2.2	91
1601	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. <i>Blood</i> , 2003 , 102, 3829-36	2.2	125
1600	HLA Peptide-mediated Strategies for Modulation of Cellular and Humoral Immune Response in Transplantation. 2003 , 1, 17-36		
1599	Nonmyeloablative allogeneic stem cell transplantation using alternative donors. 2004 , 11, 86-96		14
1598	Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma. 2004 , 51, 295-318		24
1597	Reduced-intensity hematopoietic stem cell transplantation (RIST) for solid malignancies. 2004 , 34, 707-16		2
1596	Preparation of genetically homogeneous antigen-specific thymidine kinase positive T-lymphocyte clones for the control of alloreactivity post-bone marrow transplantation. 2004 , 15, 542-52		2
1595	Adoptive Immunotherapy: Methods and Protocols. 2004 ,		
1594	Graft-versus-host disease in mini-transplant. 2004 , 45, 1969-80		10
1593	Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. 2004 , 10, 3586-92		125
1592	Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. 2004 , 22, 3886-92		88
1591	Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy. 2004 , 4, 865-75		7
1590	Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. 2004 , 22, 416-23.		156
1589	Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. 2004 , 22, 2816-25		171
1588	Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. 2004 , 64, 391-9		113
1587	Immunobiology of Organ Transplantation. 2004 ,		2

1586	Clinical implications of T cell receptor repertoire analysis after allogeneic stem cell transplantation. 2004 , 9, 189-98	9
1585	Donor lymphocyte infusions. 2004 , 51, 319-45	1
1584	Granulocyte colony-stimulating factor modulates alpha-galactosylceramide-responsive human Valpha24+Vbeta11+NKT cells. 2004 , 173, 4960-6	20
1583	Target antigens determine graft-versus-host disease phenotype. 2004 , 173, 5467-75	167
1582	A novel HLA-A*3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. 2004 , 173, 7046-54	50
1581	Nonmyeloablative allogeneic immunotherapy for solid tumors. 2004 , 55, 459-75	25
1580	Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD. 2004 , 5, 395-402	6
1579	History of pediatric stem cell transplantation. 2004 , 8 Suppl 5, 5-11	5
1578	Risk factors in pediatric stem cell transplantation for leukemia. 2004 , 8, 464-74	16
1577	Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant. 2004 , 124, 629-35	32
1576	Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. 2004 , 125, 480-93	29
1575	Chronic graft versus host disease. 2004 , 125, 435-54	134
1574	CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. 2004 , 126, 527-35	25
1573	Exploiting alloreactivity for tumour immunotherapy. 2004 , 87 Suppl 2, 227-9	5
1572	Donor APCs are required for maximal GVHD but not for GVL. 2004 , 10, 987-92	269
1571	Molecules and mechanisms of the graft-versus-leukaemia effect. 2004 , 4, 371-80	305
1570	Transplantation of highly purified peripheral-blood CD34+ progenitor cells from related and unrelated donors in children with nonmalignant diseases. 2004 , 33, 25-32	27
1569	A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant. 2004 , 33, 231-6	11

1568	Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. 2004 , 33, 491-7	20
1567	A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. 2004 , 33, 881-9	58
1566	Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy. 2004 , 33, 1137-41	9
1565	Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. 2004 , 33, 891-900	23
1564	Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation. 2004 , 33, 1131-5	7
1563	Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. 2004 , 34, 43-9	36
1562	Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. 2004 , 34, 77-84	62
1561	High-dose cytosine arabinoside and etoposide with total body irradiation as a preparatory regimen for allogeneic hematopoietic stem-cell transplantation in patients with acute lymphoblastic leukemia. 2004 , 34, 299-303	5
1560	Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. 2004 , 34, 309-16	23
1559	Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients. 2004 , 34, 433-8	9
1558	Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. 2004 , 34, 425-31	22
1557	Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. 2004 , 34, 331-7	48
1556	Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party. 2004 , 34, 711-9	25
1555	Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. 2004 , 18, 1013-9	41
1554	Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection. 2004 , 18, 1156-8	10
1553	Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. 2004 , 73, 85-92	10
1552	Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside. 2004 , 31, 4-21	30
1551	Nonmyeloablative reduced-intensity transplantation in multiple myeloma. 2004 , 31, 33-6	6

1550	Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. 2004 , 31, 47-55	19
1549	Cellular immunotherapy and cancer. 2004 , 31, 87-90	11
1548	Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. 2004 , 32, 218-23	33
1547	Effect of KRN7000 on induced graft-vs-host disease. 2004 , 32, 630-7	37
1546	A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation. 2004 , 32, 756-64	9
1545	Ganciclovir-mediated elimination of HSV-Tk+ T cells and cure of graft-vs-host disease in an allogeneic bone marrow transplantation model in the rat. 2004 , 32, 962-9	2
1544	Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. 2004 , 32, 1110-7	13
1543	Nitric oxide synthesis contributes to inhibition of graft-versus-tumor-effects against intraperitoneal Meth A tumor. 2004 , 230, 109-18	3
1542	Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes. 2004 , 83, 295-301	8
1541	Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases. 2004 , 26, 155-68	23
1540	Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts. 2004 , 26, 169-85	3
1539	Abl: the prototype of oncogenic fusion proteins. 2004 , 61, 2897-911	18
1538	The therapy of relapsed acute leukaemia in adults. 2004 , 18, 39-63	12
1537	The graft-versus-leukaemia effect after allogeneic bone-marrow transplantation: assessment through competing risks approaches. 2004 , 23, 3851-63	5
1536	Nonmyeloablative allogeneic hematopoietic stem cell transplantation for autoimmune disease. 2004 , 50, 2387-90	12
1535	Th1/Th2 cytokine profiles and their relationship to clinical features in patients following nonmyeloablative allogeneic stem cell transplantation. 2004 , 75, 78-83	15
1534	Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA. 2004 , 75, 121-7	8
1533	Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. 2004 , 110, 76-86	19

1532	Efficient transduction and selection of human T-lymphocytes with bicistronic Thy1/HSV1-TK retroviral vector produced by a human packaging cell line. 2004 , 6, 374-86	15
1531	Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. 2004 , 51, 171-89	18
1530	Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. 2004 , 22, 1136-51	254
1529	Autologous hematopoietic cell transplantation for chronic myelogenous leukemia. 2004 , 18, 715-32, xi	4
1528	The transition from bench to bedside: lessons learned in the creation of a new T-cell product for the clinic. 2004 , 6, 593-5	
1527	Immunity to chronic myelogenous leukemia. 2004 , 18, 733-52, xi-xii	9
1526	Immunomodulation: the role of hematopoietic cytokines. 2004 , 1, 80-8	3
1525	Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of GVHD by intra-bone marrow bone marrow transplantation plus donor lymphocyte infusion. 2004 , 22, 125-34	41
1524	Allogeneic hematopoietic stem cell transplantation for lymphoma. 2004 , 4, 238-49	5
1523	Novel non-viral method for transfection of primary leukemia cells and cell lines. 2004 , 2, 1	49
1522	Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens. 2004 , 10, 1-22	54
1521	Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. 2004 , 10, 195-203	42
1520	The Mortimer M. Bortin Lecture: to destroy by the reaction of immunity: the search for separation of graft-versus-leukemia and graft-versus-host. 2004 , 10, 505-23	13
1519	Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/grraft-versus-host reactivity?. 2004 , 10, 743-7	8
1518	WT1-targeted immunotherapy of leukaemia. 2004 , 33, 288-90	15
1517	Hematopoietic stem cell transplantation from alternative sources in adults with high-risk acute leukemia. 2004 , 33, 294-302	14
1516	Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?. 2004 , 22, 1696-705	203
1515	Allogeneic Hematopoietic Cell Transplantation: A Historical Perspective. 2004 , 31, 21-32	4

1514 Bone marrow engraftment studies. **2004**, Chapter 9, Unit9.17

1513	Ex vivo selection of recipient-type alloantigen-specific CD4(+)CD25(+) immunoregulatory T cells for the control of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation. 2004 , 77, S32-4		19
1512	A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. 2004 , 78, 1014-20		54
1511	Hematopoietic stem cell transplantation: a primer for the primary care physician. 2004 , 170, 1569-77		22
1510	In-vivo generation of leukaemia-derived dendritic cells. 2004 , 17, 439-451		13
1509	Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation. 2004 , 17, 479-492		8
1508	Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. 2004 , 10, 1-7		53
1507	Major and minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation. 2004 , 9, 64-71		
1506	Editorial Overview: Reduced-intensity allogeneic hematopoietic cell transplantation: shifting paradigms, new definitions, new challenges. 2004 , 9, 36-38		
1505	Application of donor lymphocytes expressing a suicide gene for early GVL induction and later control of GVH reactions after bone-marrow transplantation. 2005 , 109, 475-86		6
1504	Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets. <i>Blood</i> , 2004 , 104, 1210-6	2.2	26
1503	Graft-versus-leukemia reactions in allogeneic chimeras. <i>Blood</i> , 2004 , 103, 767-76	2.2	323
1502	Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. <i>Blood</i> , 2004 , 103, 347-52	2.2	202
1501	Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. <i>Blood</i> , 2004 , 103, 4330-5	2.2	96
1500	Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. <i>Blood</i> , 2004 , 103, 4353-61	2.2	32
1499	Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. <i>Blood</i> , 2004 , 104, 3797-803	2.2	96
1498	Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004 , 104, 340-9	2.2	158
1497	Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model. <i>Blood</i> , 2004 , 104, 4236-44	2.2	9

1496	Stem cell transplantation: graft-mediated antileukemia effects. 2005 , 109, 421-44		5
1495	Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease. 2005 , 12, 45-54		27
1494	Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. 2005 , 80, 782-8		39
1493	Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. 2005 , 28, 281-8		33
1492	Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. 2005 , 12, 435-43		31
1491	Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. <i>Blood</i> , 2005 , 105, 548-51	2.2	62
1490	Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. <i>Blood</i> , 2005 , 105, 894-901	2.2	64
1489	The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2005 , 105, 3449-57	2.2	166
1488	Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. <i>Blood</i> , 2005 , 105, 3945-50	2.2	88
1487	Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. <i>Blood</i> , 2005 , 106, 3062-7	2.2	161
1486	Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. <i>Blood</i> , 2005 , 106, 1123-9	2.2	123
1485	Catastrophic for contaminated chickens, murder on mutant mice: harmful to human hematopoiesis?. <i>Blood</i> , 2005 , 105, 3389-3390	2.2	
1484	Ph+ ALL: another success for imatinib. <i>Blood</i> , 2005 , 105, 3388-3389	2.2	1
1483	Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Blood</i> , 2005 , 106, 3314-21	2.2	58
1482	Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. <i>Blood</i> , 2005 , 106, 3308-13	2.2	88
1481	Post-transplantation dynamics of the immune response to chronic myelogenous leukemia. 2005 , 236, 39-59		29
1480	Non-pharmacologic approaches to graft-versus-host prevention. 2005 , 19, 203-11		
1479	Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoietic malignancies and marrow conditions after allogeneic bone marrow transplantation. 2005 , 3, 33-45		30

1478	Serum elastase and antithrombin-3 in patients with acute graft-vs.-host disease after bone marrow transplantation. 2005 , 19, 466-9	2
1477	The pathophysiology of acute graft-versus-host disease. 2005 , 61, 398-409	39
1476	188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. 2005 , 130, 604-13	84
1475	Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT. 2005 , 35, 183-90	11
1474	Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. 2005 , 35, 549-56	44
1473	Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. 2005 , 35, 699-705	21
1472	Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation. 2005 , 35, 921-6	11
1471	The graft-versus-lymphoma effect: clinical review and future opportunities. 2005 , 36, 1-17	31
1470	The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia. 2005 , 36, 145-50	7
1469	Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. 2005 , 36, 205-13	41
1468	Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. 2005 , 36, 183-91	40
1467	Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. 2005 , 36, 349-54	42
1466	Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'. 2005 , 36, 565-74	17
1465	Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. 2005 , 36, 511-6	31
1464	Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH). 2005 , 36, 781-5	18
1463	Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. 2005 , 36, 907-15	30
1462	Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. 2005 , 19, 829-34	143
1461	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). 2005 , 19, 2304-12	380

1460	Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. 2005 , 113, 813-30	55
1459	Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications. 2005 , 33, 505-12	16
1458	Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia. 2005 , 33, 1172-81	10
1457	Donor leukocyte infusions and graft-versus-malignancy. 2005 , 20, 113-6	3
1456	Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. 2005 , 78, 265-74	71
1455	Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. 2005 , 54, 297-306	22
1454	T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation. 2005 , 54, 1043-58	24
1453	Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and 2005, 84, 331-8	6
1452	Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment?. 2005 , 23, 213-20	3
1451	Le cancer indépendant du psychisme: un manque d'interprétation créatrice?. 2005 , 4, 105-116	1
1450	Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning. 2005 , 145-175	
1449	Stem Cell Transplantation. 2005 ,	
1448	Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease. 2005 , 65, 9735-40	8
1447	Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice. 2005 , 65, 10032-40	14
1446	Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. 2005 , 23, 9387-93	197
1445	Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. 2005 , 23, 1993-2003	277
1444	Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. 2005 , 46, 525-31	3
1443	Interleukin-1 polymorphisms and graft-vs-host disease. 2005 , 46, 517-23	14

1442	Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity. 2005 , 5, 293-311	18
1441	Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. 2005 , 11, 7164s-7170s	38
1440	Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. 2005 , 23, 7583-93	82
1439	Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. 2005 , 23, 5675-87	314
1438	GVHD: Complication and Challenge to Successful Allogeneic Hematopoietic Cell Transplantation. 2005 , 5, 585-597	
1437	Immunotherapy of hematological malignancies: what is new?. 2005 , 16 Suppl 2, ii53-62	5
1436	Hematopoietic Stem Cells: Basic Science to Clinical Applications. 2005 , 253-292	
1435	Comparison of renal injury in myeloablative autologous, myeloablative allogeneic and non-myeloablative allogeneic haematopoietic cell transplantation. 2005 , 20, 678-83	29
1434	Role of allogeneic stem cell transplantation in multiple myeloma. 2005 , 5, 455-64	2
1433	T-cell depletion to prevent GVHD after unrelated-donor marrow transplantation. 2005 , 366, 692-4	3
1432	Interferon alpha and T-cell responses in chronic myeloid leukemia. 2005 , 46, 167-75	23
1431	Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. 2005 , 46, 1251-60	39
1430	Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytryptolide (LLDT-8), through expansion of regulatory T cells. 2005 , 5, 1904-13	27
1429	Alleviation of chronic GVHD in mice by oral immunoregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect. 2005 , 66, 231-40	5
1428	Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. 2005 , 11, 85-92	49
1427	Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells. 2005 , 11, 1-12	14
1426	Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. 2005 , 11, 108-14	98
1425	Introduction to graft-versus-host disease. 2005 , 11, 17-20	8

1424	The Fcγ ₃ RIIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation. 2005 , 11, 206-12		6
1423	Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. 2005 , 11, 321-34		375
1422	Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. 2005 , 11, 403-22		36
1421	Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies. 2005 , 11, 739-54		18
1420	Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 2005 , 11, 1014-21		39
1419	[Therapeutic potential of melatonin in cancer treatment]. 2005 , 53, 265-8		4
1418	[Stress, cancer and circadian rhythm of melatonin]. 2005 , 53, 269-72		7
1417	Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. 2005 , 14, 207-19		34
1416	[Immunotherapy with allogeneic haematopoietic stem cell transplantation: current status and perspectives]. 2005 , 26, 33-40		0
1415	Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma. 2005 , 18, 129-42		8
1414	B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC. 2005 , 7, 62-73		11
1413	An overview of hematopoietic stem cell transplantation. 2005 , 26, 517-27, v		23
1412	Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. <i>Blood</i> , 2005 , 105, 2594-600	2.2	153
1411	Immunostimulants in cancer therapy. 2005 , 345-376		
1410	IL-7 in allogeneic transplant: clinical promise and potential pitfalls. 2006 , 47, 1222-8		23
1409	Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma. 2006 , 6, 1449-58		2
1408	Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion. 2006 , 43, 53-61		42
1407	Prophylaxis and treatment of acute graft-versus-host disease. 2006 , 43, 32-41		54

1406	Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. <i>Blood</i> , 2006 , 108, 1092-9	2.2	316
1405	Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. 2006 , 12, 414-21		50
1404	Marrow irradiation with high-dose ¹⁵³ Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia. 2006 , 47, 1583-92		8
1403	Immune modulation by mesenchymal stem cells. 2006 , 312, 2169-79		280
1402	CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. 2006 , 8, 3-12		39
1401	Long-Term Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation in First Chronic Phase of Chronic Myeloid Leukemia. 2006 , 1, 123-129		
1400	Low-dose cyclosporin A with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen-identical siblings: a prospective phase II study in Japanese patients. 2006 , 84, 83-9		6
1399	Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15. 2006 , 19, 281-92		2
1398	Donor leukocyte infusions in myeloid malignancies: new strategies. 2006 , 19, 737-55		30
1397	The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective. 2006 , 19, 637-53		14
1396	Adoptive transfer of allogeneic antigen-specific T cells. 2006 , 12, 9-12		37
1395	Inflammatory cytokines predominate in cases of tumor regression after hematopoietic stem cell transplantation for solid cancer. 2006 , 12, 346-54		9
1394	Modulation of graft-versus-host disease: role of regulatory T lymphocytes. 2006 , 12, 13-21		51
1393	Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide. 2006 , 12, 480-9		14
1392	Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. 2006 , 12, 623-34		57
1391	Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. 2006 , 12, 1150-60		60
1390	T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. 2006 , 12, 1318-25		49
1389	Hematopoietic stem-cell transplantation. 2006 , 354, 1813-26		1602

1388	CD4+CD25+ regulatory T lymphocytes in bone marrow transplantation. 2006 , 18, 128-35		23
1387	Nonmyeloablative allogeneic stem-cell transplantation for metastatic renal cell cancer: a review and update. 2006 , 6, 2519-28		1
1386	Perspectivas para a leucemia miéide aguda na infñcia após a observaõ de um grupo de pacientes tratados convencionalmente. 2006 , 28, 246		4
1385	Harnessing the Potential of Graft-vs-Tumor. 2006 , 235-261		
1384	. 2006 ,		1
1383	Adoptive Immunotherapy: Guidelines and Clinical Practice. 2006 , 221-231		
1382	Adoptive cellular immunotherapy. 648-660		
1381	[Fungal infection following reduced-intensity stem cell transplantation (RIST)]. 2006 , 47, 143-53		
1380	Stem Cells in Neurodegeneration and Injury. 2006 , 287-320		
1379	Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. <i>Blood</i> , 2006 , 107, 1688-95	2.2	80
1378	HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. <i>Blood</i> , 2006 , 107, 1220-6	2.2	81
1377	Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2006 , 107, 2294-302	2.2	268
1376	Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. <i>Blood</i> , 2006 , 107, 4189-93	2.2	156
1375	Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. <i>Blood</i> , 2006 , 107, 4669-77	2.2	60
1374	Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?. <i>Blood</i> , 2006 , 107, 3430-5	2.2	92
1373	Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. <i>Blood</i> , 2006 , 108, 2106-13 ^{2.2}		83
1372	Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). <i>Blood</i> , 2006 , 108, 3216-22	2.2	131
1371	Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. <i>Blood</i> , 2006 , 108, 2463-9	2.2	22

1370	RIC for MDS: the glass is half full. <i>Blood</i> , 2006 , 108, 780-781	2.2	4
1369	Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. <i>Blood</i> , 2006 , 108, 3843-50	2.2	41
1368	Cell-cycle control in erythropoiesis. <i>Blood</i> , 2006 , 108, 781-782	2.2	9
1367	Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. 2006 , 82, 913-9		45
1366	Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease. 2006 , 82, 471-8		16
1365	Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation. 2006 , 18, 107-14		24
1364	Allogeneic graft-versus-hepatoblastoma effect. 2006 , 46, 501-5		17
1363	Adoptive T-cell transfer in cancer immunotherapy. 2006 , 84, 281-9		36
1362	Rapid progression of metastatic osteosarcoma after initiation of a reduced-intensity conditioning regimen with immunosuppressive fludarabine. 2006 , 10, 822-5		2
1361	Antifungal prophylaxis following reduced-intensity stem cell transplantation. 2006 , 8, 190-202		
1360	Exploiting beneficial alloreactive T cells. 2006 , 91, 20-7		11
1359	Nonmyeloablative Hematopoietic Cell Transplantation. 2006 , 938, 328-339		55
1358	Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). 2006 , 37, 547-52		14
1357	Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. 2006 , 37, 297-305		52
1356	Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. 2006 , 37, 865-71		54
1355	Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. 2006 , 37, 1037-42		55
1354	Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation. 2006 , 38, 157-67		4
1353	Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. 2006 , 38, 539-46		33

1352	Titration graft-versus-host disease: is it worth a try?. 2006 , 38, 653-6	6
1351	Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. 2006 , 20, 1661-72	105
1350	Mesenchymal stem cells in immunoregulation. 2006 , 84, 413-21	156
1349	Shared biology of GVHD and GVT effects: potential methods of separation. 2006 , 57, 225-44	60
1348	Generation of tumor-specific T-cell therapies. 2006 , 20, 61-9	40
1347	Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. 2006 , 24, 2582-91	575
1346	Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow. 2006 , 83, 74-9	28
1345	Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms. 2006 , 36, 33-41	9
1344	Regulatory T cells in graft-versus-host disease. 2006 , 28, 25-9	9
1343	Impact of fetal-maternal tolerance in hematopoietic stem cell transplantation. 2006 , 54, 165-72	15
1342	Towards immunogene therapy of hematological malignancies. 2006 , 34, 251-63	0
1341	The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. 2006 , 33, S36-43	20
1340	Regenerative Medicine of Hematopoietic and Cardiovascular Tissues. 2006 , 305-335	1
1339	Induction of tumor immunity following allogeneic stem cell transplantation. 2006 , 90, 133-73	62
1338	Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. 2006 , 17, 1134-40	72
1337	Pediatric Hematopoietic Stem Cell Transplantation. 2006 ,	1
1336	Tissue Stem Cells. 2006 ,	3
1335	Results of genotypical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond—the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. 2006 , 24, 3959-66	40

1334	Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. 2006 , 176, 1266-73	118
1333	Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. 2006 , 176, 7761-7	324
1332	Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. 2006 , 13, 26-41	57
1331	Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. 2006 , 66, 11447-54	15
1330	Allogeneic haematopoietic stem cell transplantation: current status and future outlook. 2006 , 77-78, 23-36	28
1329	Immune responses to gene-modified T cells. 2007 , 7, 361-8	10
1328	Human Leukocyte and Granulocyte Antigens and Antibodies: The HLA and HNA Systems. 2007 , 129-156	
1327	Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2. 2007 , 2007, 47-54	7
1326	Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. 2007 , 15, 355-60	34
1325	Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. 2007 , 4, 404-14	31
1324	Monoclonal T-cell receptors: new reagents for cancer therapy. 2007 , 15, 1744-50	44
1323	Hematopoietic stem cell therapy for malignant diseases. 2007 , 39, 465-73	5
1322	Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay. 2007 , 13, 636-43	24
1321	Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease. 2007 , 13, 1029-35	7
1320	Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. 2007 , 25, 4938-45	357
1319	Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. 2007 , 25, 4262-9	52
1318	Fetal microchimerism in women with breast cancer. 2007 , 67, 9035-8	79
1317	Hematopoietic cell transplantation: progress and obstacles. 2007 , 18, 1450-6	20

1316	Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects. 2007 , 81, 176-85		42
1315	Haploidentical Stem Cell Transplantation in Childhood. 2007 , 3, 37-44		4
1314	In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. <i>Blood</i> , 2007 , 109, 2008-13	2.2	39
1313	Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. <i>Blood</i> , 2007 , 109, 3603-6	2.2	75
1312	Effective graft depletion of MiHA _g T-cell specificities and consequences for graft-versus-host disease. <i>Blood</i> , 2007 , 109, 3830-8	2.2	9
1311	Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. <i>Blood</i> , 2007 , 109, 4089-96	2.2	71
1310	Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. <i>Blood</i> , 2007 , 110, 409-17	2.2	64
1309	Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT. <i>Blood</i> , 2007 , 110, 450-60	2.2	19
1308	Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2007 , 109, 5511-9	2.2	130
1307	Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. <i>Blood</i> , 2007 , 110, 1924-32	2.2	138
1306	Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft. <i>Blood</i> , 2007 , 110, 3842-52	2.2	19
1305	CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. <i>Blood</i> , 2007 , 110, 3447-55	2.2	57
1304	Reduced intensity transplantation for metastatic renal cell cancer with 2-year follow-up. 2007 , 30, 562-6		8
1303	Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis. 2007 , 29, 750-7		20
1302	Tolerance to organ transplants: is chimerism bringing it closer than we think?. 2007 , 12, 329-334		5
1301	Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. 2007 , 84, 316-22		22
1300	Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. 2007 , 83, 1107-13		77
1299	Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents. 2007 , 84, 551-4		16

1298	Reduced-intensity stem cell transplantation for hematological malignancies: current status and the future. 2007 , 2, 149-62	6
1297	Serum elastase and antithrombin-3 levels after umbilical cord blood transplantation or bone marrow transplantation. 2007 , 12, 29-31	
1296	[To test the impact of hypnotherapy upon immunity and circadian rhythms among palliative cancer patients: a promising goal?]. 2007 , 55, 186-93	1
1295	Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. 2007 , 13, 116-23	79
1294	Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers. 2007 , 13, 151-63	4
1293	In vitro methotrexate as a practical approach to selective allodepletion. 2007 , 13, 644-54	7
1292	Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. 2007 , 13, 790-805	10
1291	Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. 2007 , 13, 1083-94	54
1290	Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy. 2007 , 28, 115-42	40
1289	Dendritic cell homeostasis and trafficking in transplantation. 2007 , 28, 353-9	20
1288	A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. 2007 , 9, 746-54	80
1287	Immunotherapy by allogeneic stem cell transplantation. 2007 , 97, 25-60	26
1286	Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells. 2007 , 25, 1595-601	39
1285	Risk assessment in haematopoietic stem cell transplantation: histocompatibility. 2007 , 20, 155-70	47
1284	Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens. 2007 , 20, 171-87	47
1283	Risk assessment in haematopoietic stem cell transplantation: conditioning. 2007 , 20, 295-310	27
1282	Risk assessment in haematopoietic stem cell transplantation: stem cell source. 2007 , 20, 265-80	16
1281	Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. 2007 , 20, 219-29	35

1280	Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. 2007 , 20, 281-94	37
1279	Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. 2007 , 20, 311-27	32
1278	Risk assessment in haematopoietic stem cell transplantation: disease and disease stage. 2007 , 20, 125-54	22
1277	Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?. 2007 , 12, 4568-94	9
1276	Donor Lymphocyte Infusions for Patients with Relapsed Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: a 10-year Experience of Seoul National University Hospital. 2007 , 42, 233	
1275	Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome. 2007 , 92, 1655-63	19
1274	Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation. 2007 , 82, 758-60	3
1273	Normal hematopoietic function and multiple bone marrow clonal abnormalities in a patient with acute myeloid leukemia after two mismatched stem-cell transplants with graft failure and autologous reconstitution. 2007 , 82, 744-7	4
1272	Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. 2007 , 25, 170-7	7
1271	Allogeneic transplantation for myelodysplastic syndrome (MDS). 2007 , 21, 61-71	14
1270	Comparing the small sample performance of several variance estimators under competing risks. 2007 , 26, 1170-80	18
1269	Graft-versus-leukemia in chronic lymphocytic leukemia. 2007 , 39, 441-6	22
1268	IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. 2007 , 39, 637-45	91
1267	Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. 2007 , 39, 751-7	194
1266	HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI. 2007 , 40, 319-27	11
1265	Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor. 2007 , 40, 339-47	21
1264	Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. 2007 , 40, 535-9	21
1263	Interleukin-7 induced facilitation of immunological reconstitution of sublethally irradiated mice following treatment with alloreactive spleen cells in a murine model of B-cell leukemia/lymphoma (BCL1). 2007 , 40, 881-9	8

1262	Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia. 2007 , 40, 1069-74	12
1261	CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. 2007 , 21, 1451-9	42
1260	Genetically identical twin transplantation for chronic lymphocytic leukemia. 2007 , 21, 2452-5	20
1259	Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation. 2007 , 20, 761-70	20
1258	Clinical importance of HLA-DPB1 in haematopoietic cell transplantation. 2007 , 69 Suppl 1, 36-41	13
1257	NK-KIR ligand identification: a quick Q-PCR approach for HLA-C epitope typing. 2007 , 69, 334-7	7
1256	Immunomodulation by mesenchymal stem cells and clinical experience. 2007 , 262, 509-25	570
1255	Advances in the understanding of acute graft-versus-host disease. 2007 , 137, 3-19	40
1254	The management and outcome of chronic graft-versus-host disease. 2007 , 138, 131-45	31
1253	Review article: Stem cell transplantation for the treatment of gastrointestinal diseases--current applications and future perspectives. 2007 , 26 Suppl 2, 77-89	8
1252	Histopathological bone marrow changes after reduced-intensity hematopoietic stem cell transplantation for follicular lymphoma involving bone marrow. 2007 , 57, 378-82	1
1251	Pretransplant treatment of donors with immunomodulators to control graft-versus-host disease (GVHD) in transplant recipients. 2007 , 35, 748-56	7
1250	Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. 2007 , 35, 1140-52	44
1249	Polymyositis complicating donor lymphocyte infusion after stem cell transplantation for relapsed chronic myeloid leukemia: report of a case and review of literature. 2007 , 26, 1207-10	5
1248	Inference for current leukemia free survival. 2008 , 14, 432-46	10
1247	Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. 2008 , 42, 84-105	30
1246	Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation. 2008 , 88, 119-120	2
1245	Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer. 2008 , 13, 176-80	5

1244	Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. 2008 , 50, 1-8	48
1243	Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. 2008 , 83, 771-7	17
1242	An Hsp70 peptide initiates NK cell killing of leukemic blasts after stem cell transplantation. 2008 , 32, 527-34	17
1241	Twelve immunotherapy drugs that could cure cancers. 2008 , 222, 357-68	255
1240	Allogeneic transplantation for ALL in adults. 2008 , 41, 439-46	19
1239	Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. 2008 , 42, 201-5	41
1238	A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation. 2008 , 42, 535-9	15
1237	Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT. 2008 , 42, 723-31	11
1236	Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation. 2008 , 41, 1029-35	35
1235	Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. 2008 , 41, 495-503	24
1234	Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. 2008 , 41, 245-52	61
1233	Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. 2008 , 41, 483-93	77
1232	Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. 2008 , 41, 505-13	45
1231	Allogeneic hematopoietic cell transplantation for metastatic breast cancer. 2008 , 41, 537-45	31
1230	Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults. 2008 , 41, 729-36	5
1229	A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. 2008 , 41, 805-12	37
1228	Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. 2008 , 41, 887-93	17
1227	Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study. 2008 , 14, 1160-6	26

1226	Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study. 2008 , 72, 549-58	17
1225	Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients. 2008 , 140, 340-3	9
1224	Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. 2008 , 141, 799-807	26
1223	Understanding and harnessing the graft-versus-leukaemia effect. 2008 , 142, 877-88	71
1222	High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian multicentre study. 1995 , 89, 790-7	19
1221	Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Soci� Fran�aise de Greffe de Moelle et de Th�rapie Cellulaire. 2008 , 36, 535-44	47
1220	Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. 2008 , 127, 348-58	80
1219	Patients suffering from acute graft-versus-host disease after bone-marrow transplantation have functional CD4+CD25hiFoxp3+ regulatory T cells. 2008 , 129, 241-8	12
1218	Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT). 2008 , 66, 73-82	1
1217	Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation. 2008 , 81, 226-35	21
1216	Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells. 2008 , 81, 281-8	22
1215	Minor histocompatibility antigens: targets for tumour therapy and transplant tolerance. 2008 , 35, 363-6	6
1214	Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic stem cell transplantation. 2008 , 35, 389-93	9
1213	Refinement of molecular approaches to improve the chance of identification of hematopoietic-restricted minor histocompatibility antigens. 2008 , 329, 125-37	1
1212	Graft-versus-host disease after donor leukocyte infusions: presentation and management. 2008 , 21, 205-22	54
1211	Impact of graft-versus-host disease on survival. 2008 , 21, 193-204	43
1210	Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect. 2008 , 21, 239-50	9
1209	Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease. 2008 , 21, 543-57	29

1208	Graft-versus-disease effect following allogeneic transplantation for acute leukaemia. 2008 , 21, 485-502		13
1207	Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. 2008 , 21, 437-53		48
1206	Donor lymphocyte infusions for acute myeloid leukaemia. 2008 , 21, 455-66		25
1205	Acute Leukemias. 2008 ,		5
1204	Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. <i>Blood</i> , 2008 , 111, 2909-18	2.2	68
1203	Regulatory CD4+CD25hi T cells conserve their function and phenotype after granulocyte colony-stimulating factor treatment in human hematopoietic stem cell transplantation. 2008 , 69, 329-37		7
1202	Patients benefit from the addition of KIR repertoire data to the donor selection procedure for unrelated haematopoietic stem cell transplantation. 2008 , 45, 981-9		14
1201	Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation. 2008 , 45, 2255-61		25
1200	"It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer. 2008 , 20, 296-300		24
1199	The phenotypical and functional characteristics of cord blood monocytes and CD14(-/low)/CD16(+) dendritic cells can be relevant to the development of cellular immune responses after transplantation. 2008 , 19, 55-63		15
1198	Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. 2008 , 14, 99-109		29
1197	The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. 2008 , 14, 499-509		29
1196	Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. 2008 , 14, 556-67		30
1195	Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. 2008 , 14, 807-16		117
1194	CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy. 2008 , 14, 973-984		33
1193	Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. <i>Blood</i> , 2008 , 112, 2232-41	2.2	59
1192	Allogeneic stem cell transplantation for myelodysplastic syndrome. 2008 , 45, 49-59		25
1191	Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. 2008 , 8, 951-68		52

1190	Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. 2008 , 8, 785-98		5
1189	Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies. 2008 , 120, 182-9		29
1188	Old and new cancers after hematopoietic-cell transplantation. 2008 , 142-9		35
1187	Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. 2008 , 93, 834-41		9
1186	Evidence for a graft-versus-leukemia effect in the central nervous system. 2008 , 49, 365-9		1
1185	PR1 vaccination in myeloid malignancies. 2008 , 7, 867-75		21
1184	Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. 2008 , 14, 2833-40		11
1183	Safety of hematopoietic stem cell transplantation in children less than three years of age. 2008 , 25, 705-22		10
1182	Innovative Leukemia and Lymphoma Therapy. 2008 ,		
1181	Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. 2008 , 180, 6892-902		11
1180	Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. 2008 , 19, 1935-40		61
1179	Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. 2008 , 49, 1494-500		2
1178	Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. <i>Blood</i> , 2008 , 111, 2476-84	2.2	136
1177	Chronic graft-versus-host disease following umbilical cord blood transplantation: retrospective survey involving 1072 patients in Japan. <i>Blood</i> , 2008 , 112, 2579-82	2.2	37
1176	Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. <i>Blood</i> , 2008 , 112, 2139-48	2.2	39
1175	Graft-versus-leukemia effects of transplantation and donor lymphocytes. <i>Blood</i> , 2008 , 112, 4371-83	2.2	460
1174	Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?. 2008 , 15, 127-33		7
1173	The use of growth factors in hematopoietic stem cell transplantation. 2008 , 14, 1950-61		53

1172	Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation: the role of oral nutrition. 2008 , 85, 1000-7	33
1171	A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease. 2008 , 85, 102-11	15
1170	Alternative donor transplants for high-risk acute myeloid leukemia. 2008 , 15, 115-20	4
1169	Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. 2008 , 30, 575-83	12
1168	Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity. 2008 , 86, 854-64	17
1167	Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMF. 2008 ,	
1166	Tumor immunology and immunotherapy. 2008 , 1181-1195	
1165	A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors. 2008 , 93, 265-72	6
1164	Hematopoietic stem cell transplantation: 40 years of continuous progress and evolution. 2008 , 93, 1607-10	5
1163	Gene and cell therapy for relapsed leukemia after allo-stem cell transplantation. 2008 , 13, 3408-14	12
1162	Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. 2009 , 94, 1399-406	32
1161	Adoptive T-cell therapy for B-cell malignancies. 2009 , 2, 517-32	7
1160	Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia. 2009 , 182, 5938-48	84
1159	Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. 2009 , 106, 19952-7	121
1158	Oxidative stress and lymphocyte persistence: implications in immunotherapy. 2009 , 102, 197-227	22
1157	Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor. 2009 , 69, 5151-8	14
1156	The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD. 2009 , 8, 1794 - 1802	22
1155	Case records of the Massachusetts General Hospital. Case 28-2009. A 68-year-old man with fatigue, cough, and peripheral-blood monocytosis. 2009 , 361, 1099-106	

1154	Novel application of lentiviral vectors towards treatment of graft-versus-host disease. 2009 , 9, 749-61	4
1153	Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia. 2009 , 9, 1217-23	19
1152	Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. 2009 , 15, 4759-68	36
1151	Expansion of allospecific regulatory T cells after energized, mismatched bone marrow transplantation. 2009 , 1, 1ra3	18
1150	Solid tumors in adults. 2009 , 137-145	
1149	The immunological impact of genetic drift in the B10.BR congenic inbred mouse strain. 2009 , 183, 4261-72	13
1148	Chronic graft-versus-host disease. 2009 , 401-407	4
1147	Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. 2009 , 106, 3889-94	31
1146	Revealing tumor immunity after hematopoietic stem cell transplantation. 2009 , 15, 4515-7	6
1145	Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. 1993 , 50, 269-74	19
1144	Management of graft-versus-host disease. 1993 , 51, 1-12	21
1143	Natural effector cells in patients with acute myeloid leukemia treated with the immunomodulator Linomide after autologous bone marrow transplantation. 1999 , 63, 251-8	1
1142	High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation. 2009 , 84, 21-8	20
1141	A simple and effective method for cancer immunotherapy by inactivated allogeneic leukocytes infusion. 2009 , 124, 1142-51	11
1140	Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. 2009 , 115, 1899-905	166
1139	Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation. 2009 , 90, 643-647	6
1138	Application of immunotherapy in pediatric leukemia. 2009 , 4, 159-66	3
1137	[Hematopoietic stem cell transplantation. Indications, foundations and perspective]. 2009 , 50, 572-80	5

1136	Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis. 2009 , 58, 429-39		13
1135	Regression analysis of mean quality-adjusted survival time based on pseudo-observations. 2009 , 28, 1054-66		3
1134	Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation. 2009 , 100, 138-43		1
1133	The allogeneic graft-versus-cancer effect. 2009 , 147, 614-33		117
1132	Does chemotherapy modify the immune surveillance of hematological malignancies?. 2009 , 23, 53-8		36
1131	Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. 2009 , 23, 1278-87		44
1130	Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis. 2009 , 43, 61-7		18
1129	Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. 2009 , 43, 709-15		28
1128	Early lymphocyte recovery after allogeneic hematopoietic SCT is associated with significant GVL effect in pediatric ALL but not acute myelogenous leukemia-Update study. 2009 , 44, 799-804		10
1127	Importance of CsA drug monitoring in SCT recipients to minimize GVHD and maximize graft vs. leukemia. 2009 , 13, 400-3		1
1126	Treating donor mice with rhIL-11 and rhG-CSF promotes transplant-tolerance and preserves the effects of GVL after allogeneic bone marrow transplantation. 2009 , 33, 123-8		3
1125	HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. <i>Blood</i> , 2009 , 113, 2851-8	2.2	110
1124	Role of reduced intensity transplant in adult patients with acute lymphoblastic leukemia: If and when?. 2009 , 22, 557-66		3
1123	Fetal microchimerism and cancer. 2009 , 276, 8-13		21
1122	Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. 2009 , 15, 257-65		235
1121	Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. 2009 , 15, 360-6		34
1120	Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. 2009 , 15, 421-31		63
1119	Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators. 2009 , 15, 406-15		6

1118	Transplantation conditioning regimens: can we say it better?. 2009 , 15, 653-5		11
1117	Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation. 2009 , 15, 903-9		4
1116	Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. 2009 , 15, 996-9		32
1115	Principles and overview of allogeneic hematopoietic stem cell transplantation. 2009 , 144, 1-21		14
1114	Bone marrow engraftment studies. 2009 , Chapter 9, Unit 9.17		2
1113	The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease. 2009 , 69, 1339-50		1
1112	Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. 2009 , 9 Suppl 3, S261-5		10
1111	Preface. Gene transfer into hematopoietic cells: from basic science to clinical application. 2009 , 506, v-xi		2
1110	Tumor-Associated Antigens in Childhood Cancer. 113-141		
1109	Lentiviral vector gene transfer into human T cells. 2009 , 506, 97-114		23
1108	La greffe de cellules souches h�matopo�iques. 2009 , 5, 16-28		1
1107	Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. 2009 , 23, 1011-31, vi		3
1106	Immunotherapy in acute leukemia. 2009 , 46, 89-99		7
1105	Role of allogeneic stem cell transplantation in multiple myeloma. 2009 , 46, 158-65		7
1104	Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation. 2009 , 5, 559-68		8
1103	A role for mesenchymal stem cells in the control of graft-versus-host disease. 2009 , 87, S53-4		7
1102	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. <i>Blood</i> , 2009 , 113, 3110-8	2.2	136
1101	Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. <i>Blood</i> , 2009 , 114, 3909-16	2.2	153

1100	Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. <i>Blood</i> , 2009 , 114, 4293-9	2.2	251
1099	Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. <i>Blood</i> , 2009 , 114, 2829-36	2.2	28
1098	Are 2 cords better than 1?. <i>Blood</i> , 2009 , 114, 3980-1	2.2	1
1097	A retrospective comparison of allogeneic peripheral blood stem cell versus bone marrow transplantation. 2009 , 2, 272-7		5
1096	Immunotherapy of childhood cancer: from biologic understanding to clinical application. 2010 , 22, 2-11		15
1095	Allogreffe de cellules souches h�matopo�iques : r�alisation et complications. 2010 , 5, 1-19		
1094	Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs. 2010 , 33, 975-82		8
1093	Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?. 2010 , 95, 660-5		12
1092	CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. 2010 , 95, 1572-8		15
1091	Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. <i>Blood</i> , 2010 , 115, 3869-78	2.2	188
1090	Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses. <i>Blood</i> , 2010 , 115, 5249-58	2.2	45
1089	Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. <i>Blood</i> , 2010 , 115, 4923-33	2.2	85
1088	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010 , 115, 453-74	2.2	2483
1087	Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. <i>Blood</i> , 2010 , 115, 1669-77	2.2	24
1086	Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study. 2010 , 59, 1511-9		16
1085	Allogeneic natural killer cells for refractory lymphoma. 2010 , 59, 1739-44		145
1084	Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy. 2010 , 58, 347-54		2
1083	High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. 2010 , 47, 65-77		139

1082	Reconstitution of self-tolerance after hematopoietic stem cell transplantation. 2010 , 47, 143-52	13
1081	Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allogeneic stem-cell transplantation in acute and chronic leukemia patients. 2010 , 91, 652-60	6
1080	Acute myeloid leukemia: when to transplant in first complete remission. 2010 , 5, 101-8	9
1079	Cord blood as a source of non-senescent lymphocytes for tumor immunotherapy. 2010 , 85, 47-50	7
1078	GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants. 2010 , 84, 323-31	13
1077	Granulocyte colony-stimulating factor produces a decrease in IFNgamma and increase in IL-4 when administrated to healthy donors. 2010 , 25, 181-7	7
1076	Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation. 2010 , 34, 1374-82	17
1075	Decrease of CD4(+)CD25(+) regulatory T cells and TGF-beta at early immune reconstitution is associated to the onset and severity of graft-versus-host disease following allogeneic haematogenesis stem cell transplantation. 2010 , 34, 1158-68	63
1074	Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. 2010 , 149, 879-89	10
1073	Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. 2010 , 24, 1462-9	54
1072	Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. 2010 , 24, 1901-9	16
1071	The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. 2010 , 24, 1852-8	49
1070	Unrelated donor marrow transplantation in children: transplant policy and outcome in Leiden Paediatrics SCT-Centre. 2010 , 45, 87-95	4
1069	Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT. 2010 , 45, 31-7	2
1068	Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. 2010 , 45, 339-47	21
1067	Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment. 2010 , 45, 177-80	5
1066	Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. 2010 , 10, 213-21	192
1065	Stem cell and cord blood transplantation âstate of the art. 2010 , 5, 317-323	0

1064	Impact on relapse of corticosteroid therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. 2010 , 24, 772-7	5
1063	Management of chronic leukemia in older adults. 230-244	
1062	Hematopoietic stem cell transplantation for the management of follicular lymphoma. 2010 , 3, 69-80	
1061	Bone Marrow Transplantation. 2010 , 198-210	
1060	CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. 2010 , 2, 41ra52	72
1059	Fetal stem cell microchimerism: natural-born healers or killers?. 2010 , 16, 869-78	36
1058	The role of bacteria and pattern recognition receptors in GVHD. 2010 , 2010, 814326	23
1057	Immune-based therapeutics for pediatric cancer. 2010 , 10, 163-78	15
1056	Change in serum proteome during allogeneic hematopoietic stem cell transplantation and clinical significance of serum C-reactive protein and haptoglobin. 2010 , 42, 651-61	10
1055	Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. 2010 , 21, 241-50	55
1054	Acute Myelogenous Leukemia. 2010 ,	
1053	My approach to the immunogenetics of haematopoietic stem cell transplant matching. 2010 , 63, 194-8	3
1052	Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients. 2010 , 45, 862-71	18
1051	Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. 2010 , 70, 906-15	48
1050	Immunotherapy for renal cell carcinoma. 2010 , 2010, 284581	50
1049	Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. 2010 , 18, 1748-57	56
1048	Suicide gene therapy for graft-versus-host disease. 2010 , 2, 521-37	4
1047	The graft-versus-tumor effect in pediatric malignancy. 2010 , 57, 67-81	8

1046	Reduced intensity conditioning for hematopoietic stem cell transplantation: has it achieved all it set out to?. 2010 , 12, 440-54		4
1045	Cellular immunotherapy of cancer. 2010 , 651, 319-45		8
1044	Umbilical cord blood transplantation from unrelated donors in adult patients with chronic myeloid leukaemia. 2010 , 23, 217-22		3
1043	How closely related is graft-vs-leukemia to donor/recipient disparity?. 2010 , 23, 525-8		5
1042	Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. 2010 , 36, 528-38		101
1041	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. 2010 , 16, 871-90		85
1040	Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. 2010 , 16, 1728-37		20
1039	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. 2010 , 16, 1467-503		107
1038	Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. 2010 , 22, 162-72		27
1037	Selecting unrelated donor grafts to prevent leukaemia relapse. 2010 , 11, 608-9		1
1036	RNA therapeutics: function, design, and delivery. Preface. 2010 , 629, v-vii		5
1035	Immunotherapy of Cancer. 2010 ,		1
1034	Hematopoietic Stem Cell Biology. 2010 ,		3
1033	Cancer vaccines in hematologic malignancies: advances, challenges and therapeutic potential. 2010 , 9, 451-4		1
1032	Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. <i>Blood</i> , 2011 , 117, 764-71	2.2	185
1031	Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. 2011 , 11, 763-73		7
1030	Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. 2011 , 11, 855-73		111
1029	Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. 2011 , 11 Suppl 1, S96-100		3

1028 Graft-Versus-Host Disease. **2011**, 178.1-178.12

1027 Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. **2011**, 25, 1025-48, vi 8

1026 Vaccination strategies in lymphomas and leukaemias: recent progress. **2011**, 71, 1659-74 15

1025 Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. **2011**, 11, 473-87 81

1024 Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions. **2011**, 25, 1189-213 5

1023 Novel intervention for eliminating VRE from the environment. **2011**, 171, 1684-5 2

1022 Novel transplant strategies in adults with acute leukemia. **2011**, 25, 1319-39, ix

1021 Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. *Blood*, **2011**, 117, 2307-18 2.2 139

1020 Principles of Immunopharmacology. **2011**, 3

1019 Childhood Leukemia. **2011**, 6

1018 [Is fetal microchimerism beneficial for the fetus or the mother?]. **2011**, 39, 224-31 4

1017 Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. **2011**, 24, 65-72 72

1016 Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. **2011**, 24, 339-49 16

1015 Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. **2011**, 24, 359-68 43

1014 T cell gene-engineering to enhance GVT and suppress GVHD. **2011**, 24, 421-33 2

1013 Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation. **2011**, 17, 374-83 11

1012 Prognostic factors for outcomes of pediatric patients with refractory or relapsed acute leukemia undergoing allogeneic progenitor cell transplantation. **2011**, 17, 516-23 10

1011 Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. **2011**, 17, 821-30 115

1010	Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006. 2011 , 17, 1187-95		20
1009	Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. 2011 , 17, 1698-703		16
1008	Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. 2011 , 17, 1688-97		106
1007	Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia. 2011 , 17, 1723-4		8
1006	[Fetal microchimerism: self and non-self, finally who are we?]. 2011 , 40, 387-98		1
1005	Transplantation of CD6-depleted peripheral blood stem cells after DLA-haploidentical bone marrow transplantation contributes to engraftment and tolerance in a preclinical model of stem cell transplantation. 2011 , 144, 27-35		1
1004	Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome. 2011 , 23, 50-7		11
1003	Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. 2011 , 44, 205-10		18
1002	Mesenchymal stromal cells for graft-versus-host disease. 2011 , 22, 257-62		48
1001	Treatment of chronic graft-versus-host disease: Past, present and future. 2011 , 46, 153-63		65
1000	Immune Reactions following Cord Blood Transplantations in Adults. 2011 , 2011, 607569		4
999	Dendritic cells in cord blood transplantation: a review. 2011 , 2011, 539896		5
998	A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR. 2011 , 6, e21699		20
997	Favorable outcomes after allogeneic hematopoietic stem cell transplantation in children with high-risk or advanced acute myeloid leukemia. 2011 , 33, 281-8		10
996	Immunotherapy for myeloproliferative neoplasms (MPN). 2011 , 11, 72-84		5
995	Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention. <i>Blood</i> , 2011 , 117, 2975-83	2.2	42
994	HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection. <i>Blood</i> , 2011 , 118, 3969-78	2.2	51
993	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011 , 118, 456-63	2.2	69

992	Next-generation leukemia immunotherapy. <i>Blood</i> , 2011 , 118, 2951-9	2.2	53
991	Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. <i>Blood</i> , 2011 , 118, 5319-29	2.2	13
990	Tacrolimus versus cyclosporine A for prevention of graft versus host disease after stem cell transplantation. 2011 ,		
989	WT1-specific CTL cells of recipient origin may exist in the peripheral blood of patients achieving full donor chimerism soon after nonmyeloablative transplantation. 2011 , 25, 689-96		
988	On the future of HLA. 2011 , 78, 229-40		7
987	Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. 2011 , 89, 396-407		88
986	Pre-engraftment graft-versus-host disease after allogeneic hematopoietic cell transplantation for acute leukemia. 2011 , 87, 172-81		5
985	The role of regulatory T cells during the attenuation of graft-versus-leukemia activity following donor leukocyte infusion in mice. 2011 , 35, 1549-56		5
984	A case for the graft-versus-host disease as a model for B cell-mediated autoimmunity. 2011 , 10, 218-21		2
983	On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. 2011 , 140, 152-9		23
982	Three decades of transplantation for chronic myeloid leukemia: what have we learned?. <i>Blood</i> , 2011 , 117, 755-63	2.2	80
981	Costimulatory blockade with monoclonal antibodies to induce alloanergy in donor lymphocytes. 2011 , 93, 594-601		4
980	Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis. 2011 , 93, 765-770		1
979	Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia. 2011 , 94, 463-71		12
978	New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia. 2011 , 86, 619-21		3
977	The impact of osteoporosis (as measured by lumbar spine quantitative computed tomography) on disease activity and survival in myeloma patients: a 13-year prospective study. 2011 , 86, 617-9		5
976	Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar HBB haplotypes but higher HbF levels than African Americans. 2011 , 86, 612-4		26
975	Hematological characteristics and effective screening for compound heterozygosity for Hb constant spring and deletional β -thalassemia. 2011 , 86, 615-7		4

974	Proportions of bone marrow lymphocyte subsets at diagnosis may predict survival in patients with newly diagnosed diffuse large B-cell lymphoma independently of the international prognostic index. 2011 , 86, 622-4	
973	Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. 2011 , 86, 627-30	9
972	Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. 2011 , 86, 625-7	7
971	Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. 2011 , 86, 610-1	61
970	Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. 2011 , 86, 918-22	84
969	N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro. 2011 , 41, 1143-53	9
968	Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006. 2011 , 117, 4238-46	43
967	Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. 2011 , 23, 299-305	31
966	The immune reconstitution after an allogeneic stem cell transplant correlates with the risk of graft-versus-host disease and cytomegalovirus infection. 2011 , 35, 1124-6	9
965	Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant. 2011 , 187, 1653-63	25
964	Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. 2011 , 4, 17-29	37
963	Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT. 2011 , 46, 1444-9	10
962	Effects of BCR-ABL inhibitors on anti-tumor immunity. 2011 , 18, 5174-84	15
961	Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation. 2011 , 22, 829-41	24
960	Treatment of advanced leukemia in mice with mRNA engineered T cells. 2011 , 22, 1575-86	149
959	Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade. 2011 ,	7
958	Cellular therapy following allogeneic stem-cell transplantation. 2011 , 2, 409-28	7
957	C6 Immunostimulants in cancer therapy. 2011 , 373-410	

956	Adoptive Immunotherapy after Allogeneic Hematopoietic Progenitor Cell Transplantation: New Perspectives for Transfusion Medicine. 2011 , 38, 173-182	2
955	Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. 2011 , 2011, 292-8	25
954	Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. 2011 , 4, 1-9	2
953	Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4- subset dynamics and correlates with remission state. 2011 , 186, 4490-9	71
952	Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. 2011 , 17, 77-88	143
951	Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. 2011 , 11, 655-66	2
950	Gene therapy with IgG-HY fusion proteins to reduce male-specific T-cell reactivity in vitro. 2011 , 22, 44-54	4
949	Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. 2011 , 46, 641-9	20
948	Tolerance-inducing strategies in islet transplantation. 2012 , 2012, 396524	13
947	Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients. 2012 , 47, 1513-9	22
946	Use of TK-cells in haploidentical hematopoietic stem cell transplantation. 2012 , 19, 427-33	29
945	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. 2012 , 47, 831-7	28
944	Commentary: does immune suppression increase risk of developing acute myeloid leukemia?. 2012 , 26, 422-3	34
943	Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan. 2012 , 26, 1482-6	26
942	A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease. 2012 , 189, 4719-27	23
941	Current and Potential Uses of Immunocytokines as Cancer Immunotherapy. 2012 , 1, 149-171	29
940	NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome. 2012 , 2012, 180391	8
939	Improving TCR Gene Therapy for Treatment of Haematological Malignancies. 2012 , 2012, 404081	11

938	Evaluation of prognostic factors among patients with chronic graft-versus-host disease. 2012 , 97, 1187-95		10
937	Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. 2012 , 19, 54-67		22
936	Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma. 2012 , 21, 1397-406		25
935	Distinct oligoclonal T cells are associated with graft versus host disease after stem-cell transplantation. 2012 , 93, 949-57		15
934	Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy. 2012 , 97, 1678-85		10
933	Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. <i>Blood</i> , 2012 , 119, 273-84	2.2	9
932	Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2012 , 119, 3142-50	2.2	11
931	cGVHD of skin: simple tools, great advances. <i>Blood</i> , 2012 , 120, 2537-8	2.2	
930	Keep up the heat on IL-1. <i>Blood</i> , 2012 , 120, 2538-9	2.2	10
929	Advances in stem cell mobilization. 2012 , 26, 267-78		48
928	Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. 2012 , 26, 2462-8		133
927	Is graft-versus-leukemia more effective using reduced-intensity conditioning compared with myeloablative conditioning?. 2012 , 18, 1615-7		1
926	Roles of transforming growth factor- β in graft-versus-host and graft-versus-tumor effects. 2012 , 18, 1329-40		11
925	Recent advances in the understanding and treatment of pediatric leukemias. 2012 , 59, 329-58		11
924	Extensive dental caries in patients with oral chronic graft-versus-host disease. 2012 , 18, 1573-9		24
923	Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity. 2012 , 39, 643-52		23
922	Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. 2012 , 109, 2509-14		69
921	Transplantation in the onco-hematology field: focus on the manipulation of B and T cells. 2012 , 208, 67-73		23

920	Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. 2012 , 47, 1474-8	29
919	Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. 2012 , 5, 409-25	15
918	Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. 2012 , 18, 5761-72	45
917	Real-time in vivo cellular imaging of graft-versus-host disease and its reaction to immunomodulatory reagents. 2012 , 144, 33-40	1
916	Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors. 2012 , 18, 100-5	17
915	Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. 2012 , 18, 600-7	45
914	Mesenchymal stromal cells: a new tool against graft-versus-host disease?. 2012 , 18, 822-40	81
913	CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation. 2012 , 18, 887-93	22
912	Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes. 2012 , 18, 1136-43	21
911	Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study. 2012 , 47, 46-53	26
910	Acute graft-versus-host disease in pediatric allogeneic hematopoietic stem cell transplantation. Single-center experience during 10 yr. 2012 , 16, 887-93	17
909	Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. 2012 , 39, 707-15	38
908	Advances in Stem Cell Research. 2012 ,	1
907	Spender T-Zellen kontrolliert lenken. 2012 , 15, 22-26	
906	Regenerative Therapies for Hematopoietic and Cardiovascular Tissues. 2012 , 393-426	
905	Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia. 2012 , 18, 1897-904	24
904	Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. 2012 , 18, 1727-33	100
903	T-cell phosphokinome as a fingerprint of effective graft versus leukemia. 2012 , E4, 721-733	

902	Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia. 2012 , 30, 1581-6		41
901	Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution. 2012 , 29, 2348-58		3
900	Human V β V α T cells specifically recognize and kill acute myeloid leukemic blasts. 2012 , 188, 4701-8		83
899	Challenges in T cell receptor gene therapy. 2012 , 14, 386-99		31
898	The determinants of tumour immunogenicity. 2012 , 12, 307-13		248
897	The interferon-dependent orchestration of innate and adaptive immunity after transplantation. <i>Blood</i> , 2012 , 119, 5351-8	2.2	35
896	Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. 2012 , 118, 2411-9		23
895	Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation. 2012 , 157, 220-9		5
894	Cellular immunotherapy for cancer. Past, present, future. 2012 , 5, 81-84		1
893	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. 2012 , 91, 931-9		56
892	Activated T cells from umbilical cord blood armed with anti-CD3 \times anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants. 2012 , 52, 63-75		6
891	Genetic engineering of T cells for the immunotherapy of haematological malignancies. 2012 , 79, 4-14		6
890	Frequencies of 10 autosomal minor histocompatibility antigens in Korean population and estimated disparities in unrelated hematopoietic stem cell transplantation. 2012 , 79, 42-9		3
889	Graft-versus-host disease. 2012 , 9, 38-40		
888	Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. 2012 , 272, 472-83		29
887	The cellular cancer resistance of the SR/CR mouse. 2012 , 120, 974-87		1
886	The effect of HLA disparity on clinical outcome after HLA-haploidentical blood and marrow transplantation. 2012 , 26, 284-91		31
885	Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. 2012 , 26, 635-43		41

884	A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice. 2012 , 130, 365-76	12
883	T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells. 2012 , 130, 1821-32	6
882	Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. 2013 , 53, 412-8; quiz 411	38
881	Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report. 2013 , 7, 18	1
880	Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. 2013 , 5, 859-68	8
879	Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia. 2013 , 92, 1389-95	24
878	Comparative analysis of T-cell depletion method for clinical immunotherapy-anti-hepatitis c effects of natural killer cells via interferon- γ production. 2013 , 45, 2045-50	6
877	Impact of pre-transplant marrow blasts on survival of allogeneic stem cell transplantation in adult acute myeloid leukemia. 2013 , 97, 640-9	3
876	Stem Cells and Cancer Stem Cells, Volume 10. 2013 ,	
875	Microsatellite scanning of the immunogenome associates MAPK14 and ELTD1 with graft-versus-host disease in hematopoietic stem cell transplantation. 2013 , 65, 417-27	8
874	Tumor Ablation. 2013 ,	7
873	Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. 2013 , 24, 717-27	84
872	Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease. 2013 , 19, 314-20	19
871	Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. 2013 , 19, 949-57	61
870	MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. 2013 , 5, 203ra125	140
869	Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. 2013 , 26, 297-300	19
868	Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. 2013 , 98, 463-71	3
867	Immune evasion in acute myeloid leukemia: current concepts and future directions. 2013 , 1,	54

866	Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. 2013 , 19, 1244-53	70
865	Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors. 2013 , 19, 291-7	6
864	Granzyme B-mediated damage of CD8+ T cells impairs graft-versus-tumor effect. 2013 , 190, 1341-50	20
863	Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease and Graft Failure After Hematopoietic Stem Cell Transplantation and Future Challenges. 2013 , 173-205	2
862	Assessing response of therapy for acute and chronic graft-versus-host disease. 2013 , 6, 103-7	6
861	Notch signaling in hematopoietic cell transplantation and T cell alloimmunity. 2013 , 27, 269-77	9
860	Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. 2013 , 19, 1094-101	21
859	Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. 2013 , 19, 792-8	22
858	Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience. 2013 , 19, 495-9	16
857	Clinical characteristics and outcome of isolated extramedullary relapse in acute leukemia after allogeneic stem cell transplantation: a single-center analysis. 2013 , 37, 372-7	16
856	Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom. 2013 , 19, 860-6	12
855	Cellular mechanism for granulocyte-colony stimulating factor in the prevention of graft-versus-host disease in combined bone marrow and peripheral blood transplantation for hematological malignancies: the composition in collection. 2013 , 48, 3-9	7
854	Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. 2013 , 19, 274-82	33
853	Immunotherapeutic strategies for relapse control in acute myeloid leukemia. 2013 , 27, 209-16	60
852	New ways to separate graft-versus-host disease and graft-versus-tumour effects after allogeneic haematopoietic stem cell transplantation. 2013 , 160, 133-45	14
851	Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon- γ 2013 , 210, 605-21	58
850	Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. 2013 , 81, 183-93	61
849	A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT. 2013 , 48, 1205-11	5

848	Overview of the immune biology of allogeneic hematopoietic stem cell transplantation. 2013 , 1-17	2
847	B and T cells in chronic graft-versus-host disease and graft-versus-leukemia. 2013 , 299-326	
846	Proteomics in graft-versus-host disease and graft-versus-leukemia. 2013 , 449-478	2
845	IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD. 2013 , 48, 722-8	20
844	Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. 2013 , 20, 1029-32	48
843	Generation of Antigen-Specific T Lymphocytes from Induced Pluripotent Stem Cells for Adoptive Immunotherapy. 2013 , 105-121	
842	Allogeneic stem cell transplantation for chronic myeloid leukemia. 2013 , 8, 43-51	6
841	Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect. 2013 , 64, 101-17	19
840	Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 2013 , 19, 940-8	17
839	Treatment of patients with advanced cancer with the natural killer cell line NK-92. 2013 , 15, 1563-70	289
838	Treatment and management of graft-versus-host disease: improving response and survival. 2013 , 4, 366-78	93
837	Reprogramming donor T cells for adoptive immunotherapy. 2013 , 5, 1287-9	
836	Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia. 2013 , 14, 916-21	11
835	Cancer stem cells in pediatric sarcomas. 2013 , 3, 168	41
834	Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. 2013 , 25 Suppl 3, S1-13; quiz S14-6	15
833	Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR V β spectratype analysis in a murine bone marrow transplantation model. 2013 , 190, 447-57	11
832	Blockade of TGF- β signaling greatly enhances the efficacy of TCR gene therapy of cancer. 2013 , 191, 3232-9	33
831	Increasing hematopoietic stem cell yield to develop mice with human immune systems. 2013 , 2013, 740892	7

830	Soluble human leukocyte antigen G molecule expression in allogeneic hematopoietic stem cell transplantation: good predictor of acute graft-versus-host disease. 2013 , 130, 160-8		16
829	A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. 2013 , 27, E368-74		41
828	Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. 2013 , 2013, 56-62		28
827	In vivo activation of transferred regulatory T cells specific for third-party exogenous antigen controls GVH disease in mice. 2013 , 43, 2263-72		11
826	Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord. 2013 , 43, 430-9		50
825	Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning. 2013 , 27, 2113-7		12
824	Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. 2013 , 31, 1530-8		164
823	Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation. <i>Blood</i> , 2013 , 121, 1896-905	2.2	48
822	Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. <i>Blood</i> , 2013 , 122, 749-58	2.2	178
821	CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. <i>Blood</i> , 2013 , 122, 3461-72	2.2	246
820	Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. 2013 , 98, 814-22		58
819	The role of mesenchymal stem cells in hematopoietic stem cell transplantation: from bench to bedside. 2013 , 22, 723-9		36
818	Cellular therapy. 209-234		
817	Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. 2013 , 8, e55818		92
816	Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. 2013 , 4, 15		90
815	Immunotherapy for pediatric leukemia. 2013 , 3, 166		9
814	Lithothamnion muelleri controls inflammatory responses, target organ injury and lethality associated with graft-versus-host disease in mice. 2013 , 11, 2595-615		9
813	Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines. 2013 , 35, 56-61		5

812	Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experience. 2014 , 21, e434-40	1
811	The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantation. 2014 , 5, 337	48
810	Graft versus Leukemia Could Participate of Efficacy of Blinatumomab in Patients with B-Lineage Acute Lymphoid Leukemia Relapsing after Stem Cell Transplantation. 2014 , 04,	1
809	Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab. 2014 , 3, 79-89	1
808	Adoptive Immunotherapy for Acute Myeloid Leukemia: From Allogeneic Hematopoietic Cell Transplantation to CAR T Cells. 2014 , 02,	
807	Immunotherapy in acute myeloid leukemia. 2014 , 6, 95-106	25
806	Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD. 2014 , 49, 1076-83	12
805	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. 2014 , 99, 1618-23	23
804	Donor-derived CD4(+)/CCR7(+) T-cell partial selective depletion does not alter acquired anti-infective immunity. 2014 , 49, 611-5	4
803	In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells. 2014 , 22, 634-644	19
802	Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis. 2014 , 49, 1412-8	18
801	Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?. 2014 , 5, 613	12
800	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. 2014 , 5, 122	62
799	The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. 2014 , 46, 384-96	12
798	Cytotoxic T lymphocytes for leukemia and lymphoma. 2014 , 2014, 565-9	15
797	Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. 2014 , 28, 2235-40	69
796	Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. 2014 , 257, 165-80	41
795	Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children. 2014 , 166, 229-39	28

794	Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients. 2014 , 92, 137-46		10
793	Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. 2014 , 89, 795-802		34
792	Transplantation: moving to the next level. 2014 , 258, 5-11		1
791	Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. 2014 , 164, 366-75		43
790	Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults. 2014 , 14 Suppl, S6-13		7
789	Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. <i>Blood</i> , 2014 , 124, 344-53	2.2	284
788	[Current indications of allogeneic stem cell transplant in adults with acute myeloid leukemia]. 2014 , 101, 856-65		1
787	The parametric g-formula for time-to-event data: intuition and a worked example. 2014 , 25, 889-97		88
786	Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?. 2014 , 98, 569-77		8
785	CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia. 2014 , 8, 825-830		4
784	Alpha/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors. 2014 , 2014, 578741		24
783	Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation. 2014 , 89, 75-81		20
782	Urine as a source for clinical proteome analysis: from discovery to clinical application. 2014 , 1844, 884-98		70
781	Recent advances in transplantation for primary immune deficiency diseases: a comprehensive review. 2014 , 46, 131-44		14
780	Immunology and immunotherapy of chronic myeloid leukemia. 2014 , 9, 17-23		21
779	Peptide vaccines for hematological malignancies: a missed promise?. 2014 , 99, 107-16		6
778	Allogeneic transplantation as anticancer immunotherapy. 2014 , 27, 38-45		20
777	Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. 2014 , 20, 2215-25		142

776	Impact of sex incompatibility on the outcome of single-unit cord blood transplantation for adult patients with hematological malignancies. 2014 , 49, 634-9	7
775	T-cell receptor excision circle levels after allogeneic stem cell transplantation are predictive of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome. 2014 , 23, 1559-67	7
774	Hematopoietic Cell Transplantation in Children with Cancer. 2014 ,	2
773	Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. 2014 , 28, 249-61	13
772	Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. 2014 , 2, 1059-70	52
771	Transplantation tolerance: from theory to clinic. 2014 , 258, 64-79	30
770	Adoptive T-cell therapy for Leukemia. 2014 , 2, 25	13
769	Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCCG). 2014 , 7, 59	33
768	Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. 2014 , 93, 1345-51	8
767	"Designed" grafts for HLA-haploidentical stem cell transplantation. <i>Blood</i> , 2014 , 123, 967-73	2.2 63
766	Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. 2014 , 14, 947-54	18
765	Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells. 2014 , 20, 26-36	8
764	Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial. 2014 , 20, 58-65	36
763	Extracorporeal photopheresis in acute and chronic graft-versus-host disease. 2014 , 50, 349-57	33
762	[The impact of donor naive and memory T cell subsets on patient outcome following allogeneic stem cell transplantation: relationship between infused donor CD4+/CCR7+ T cell subsets and acute graft-versus-host disease]. 2014 , 62, 123-8	6
761	Complications of allogeneic hematopoietic stem cell transplantation. 2014 , 32, 349-62	50
760	New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL. 2014 , 49, 1259-65	17
759	Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies. 2014 , 6, 380-90	6

758	HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. <i>Blood</i> , 2014 , 124, 638-44	2.2	286
757	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. <i>Blood</i> , 2014 , 123, 2017-25	2.2	93
756	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <i>Blood</i> , 2014 , 124, 3817-27	2.2	128
755	HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. <i>Blood</i> , 2014 , 124, 3996-4003	2.2	111
754	GVHD prophylaxis made safe, easy, and inexpensive. <i>Blood</i> , 2014 , 124, 3672-3	2.2	3
753	Histamine dihydrochloride for maintaining remission in acute myeloid leukemia. 2014 , 3, 137-143		
752	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. 2015 , 21, 2154-2159		19
751	Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice. 2015 , 87, 334-45		3
750	Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after cord blood transplantation. 2015 , 4, 74-81		
749	Tissue typing and its role in transplantation. 2015 , 10, 115-123		1
748	Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy. 2015 , 90, 715-8		3
747	Challenges and opportunities of allogeneic donor-derived CAR T cells. 2015 , 22, 509-515		68
746	Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission. 2015 , 10, e0119595		10
745	The Genotype of the Donor for the (GT) _n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. 2015 , 10, e0140454		8
744	G-CSF-primed BM for allogeneic SCT: revisited. 2015 , 50, 892-8		8
743	Reduced-intensity conditioned allogeneic SCT in adults with AML. 2015 , 50, 759-69		28
742	T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells. 2015 , 50 Suppl 2, S43-50		11
741	The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. <i>Blood</i> , 2015 , 125, 3230-5	2.2	33

740	Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?. 2015 , 50, 1173-9		46
739	Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T Cells in Cancer Immunotherapy. 2015 , 263-282		
738	Haploidentical HSCT: a 15-year experience at San Raffaele. 2015 , 50 Suppl 2, S67-71		4
737	The Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release. 2015 , 194, 5223-32		35
736	Next generation HLA-haploidentical HSCT. 2015 , 50 Suppl 2, S63-6		9
735	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. <i>Blood</i> , 2015 , 125, 3501-8	2.2	135
734	[(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. 2015 , 23, 1110-1122		15
733	Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. 2015 , 50, 1157-67		18
732	Adoptive T-cell therapy for cancer: The era of engineered T cells. 2015 , 45, 2457-69		60
731	Allo-reactive T cells for the treatment of hematological malignancies. 2015 , 9, 1894-903		24
730	Overview: New Modality for Cancer Treatment. 2015 , 89 Suppl 1, 33-5		4
729	Directed T-cell therapies for leukemia and lymphoma after hematopoietic stem cell transplant: beyond chimeric antigen receptors. 2015 , 4, 99-111		
728	Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?. 2015 , 21, 713-9		26
727	Hematopoiesis in Regenerative Medicine. 2015 , 375-401		
726	Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity. 2015 , 112, 1125-30		31
725	Chronic Graft-Versus-Host Disease. 2015 , 245-258		
724	Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Soci� Francaise de Greffe de Moelle et de Th�rapie Cellulaire. 2015 , 21, 1059-67		19
723	The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. 2015 , 128, 1-68		34

722	Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy. <i>Blood</i> , 2015 , 125, 261-72	2.2	12
721	Cytokines in Graft-versus-Host Disease. 2015 , 194, 4604-12		112
720	Do human leukocyte antigen E polymorphisms influence graft-versus-leukemia after allogeneic hematopoietic stem cell transplantation?. 2015 , 43, 149-57		15
719	Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation. 2015 , 32, 131-9		4
718	Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes. 2015 , 21, 1237-45		16
717	The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs. 2015 , 10, 331-43		5
716	The role of gamma delta T cells in haematopoietic stem cell transplantation. 2015 , 81, 459-68		43
715	Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells. 2015 , 6, 76		12
714	Blood and Marrow Transplant Handbook. 2015 ,		5
713	The role of the killer cell immunoglobulin-like receptor (KIR) "missing self" model in unrelated donor HSCT: a meta-analysis. 2015 , 47, 558-65		8
712	siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice. 2015 , 64, 645-54		32
711	Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. 2015 , 21, 1000-7		28
710	State-of-the-art acute and chronic GVHD treatment. 2015 , 101, 452-66		47
709	[Allogeneic haematopoietic stem cell transplantation - an overview]. 2015 , 232, 641-6		2
708	T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. 2015 , 100, 709-19		20
707	High HLA-DP Expression and Graft-versus-Host Disease. 2015 , 373, 599-609		186
706	Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor. 2015 , 53, 23-9		17
705	Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. 2015 , 42, 562-72		28

704	Regulation of hematopoietic and leukemic stem cells by the immune system. 2015 , 22, 187-98	149
703	As time goes by. 2015 , 21, 1-2	6
702	Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. 2015 , 21, 89-96	9
701	Is any donor too old?. 2015 , 21, 2-3	2
700	Hematopoietic cell transplantation and cellular therapeutics in the treatment of childhood malignancies. 2015 , 62, 257-73	7
699	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. 2015 , 21, 2020-8	69
698	Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial. 2015 , 121, 562-9	25
697	Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice. 2015 , 71, 201-9	9
696	Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. 2015 , 94, 275-82	29
695	Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention. 2016 , 101, e214-5	1
694	Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets. 2016 , 7, 100	58
693	Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications. 2016 , 7, 500	28
692	T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome. 2016 , 17,	11
691	Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies. 2016 , 11, e0155165	10
690	Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation - A comparison of the last two decades. 2016 , 20, 667-74	19
689	Is there really a specific graft-versus-leukaemia effect?. 2016 , 51, 1413-1415	11
688	Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome. 2016 , 34, 357-66	58
687	Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study. 2016 , 96, 236-44	6

686	Tacrolimus versus cyclosporine A for prevention of graft versus host disease after stem cell transplantation. 2016,		
685	. 2016, 103 Suppl 1, S164-S174		
684	Complete response of extramedullary relapse in breast of acute T lymphoblastic leukemia after bone marrow transplantation to chemoradiotherapy: a case report and literature review. 2016, 16, 875		3
683	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. 2016, 4, 90		14
682	Isolated extramedullary cutaneous relapse despite concomitant severe graft-vs.-host disease and tissue chimerism analysis in a patient with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: A case report. 2016, 5, 745-749		2
681	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. 2016 , 17, 31		47
680	Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy. 2016, 101, 482-90		1
679	Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants. <i>Blood,</i> 2016, 127, 1539-43	2.2	24
678	Alloantigen presentation and graft-versus-host disease: fuel for the fire. <i>Blood,</i> 2016, 127, 2963-70	2.2	38
677	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. 2016, 101, 1251-1259		17
676	Cellular Engineering for the Production of New Blood Components. 2016, 492-520		
675	The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation. 2016, 77, 79-88		10
674	Biology of the Human Graft-versus-Tumor Response and How to Exploit It. 2016, 166-181		1
673	Reduced-intensity Allogeneic Transplantation Regimens. 2016, 232-246		
672	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults. 2016, 588-601		
671	Hematopoietic Cell Transplantation for Renal Cell Carcinoma and Other Solid Tumors. 2016, 748-761		
670	Relapse of Hematologic Malignancy After Allogeneic Hematopoietic Transplantation. 2016, 836-844		
669	Chronic Graft-versus-Host Disease – Clinical Manifestations and Therapy. 2016, 1020-1039		1

668	Mismatched unrelated donor transplantation. 2016 , 53, 230-236		4
667	Comment: Shall Killer Cell Immunoglobulin-Like Receptor Genotyping be Incorporated in Donor Search Algorithms?. 2016 , 22, 1539-1540		1
666	Matched unrelated donor transplants-State of the art in the 21st century. 2016 , 53, 221-229		6
665	Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. 2016 , 175, 191-207		74
664	Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. <i>Blood</i> , 2016 , 127, 1361-70	2.2	68
663	Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells. 2016 , 62, 49-63		28
662	Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview. 2016 , 76, 6445-6451		98
661	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. <i>Blood</i> , 2016 , 128, 1979-1986	2.2	49
660	Commentary: How do haematopoietic cell transplants cure leukaemia?. 2016 , 103, 396-8		
659	How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety. 2016 , 17, 1517-26		1
658	Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?. 2016 , 51, 640-2		6
657	Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: rationale, strategies and perspectives. 2016 , 30, 297-307		16
656	HLA mismatching as a strategy to reduce relapse after alternative donor transplantation. 2016 , 53, 57-64		37
655	Negative Impact of Unidirectional Host-versus-Graft Killer Cell Immunoglobulin-like Receptor Ligand Mismatch on Transplantation Outcomes after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia. 2016 , 22, 316-323		9
654	Retrospective analysis of adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: A multicenter experience of daily practice. 2016 , 54, 41-7		4
653	Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis. 2016 , 51, 698-704		15
652	Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation. 2016 , 8, 57-68		7
651	Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. 2016 , 51, 351-7		37

650	Novel immunotherapies in lymphoid malignancies. 2016 , 13, 25-40	172
649	The hematopoietic system in the context of regenerative medicine. 2016 , 99, 44-61	37
648	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. 2016 , 22, 112-8	27
647	Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. 2016 , 67, 59-72	32
646	Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?. 2016 , 30, 447-55	62
645	Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. 2017 , 77, 237-245	84
644	Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults. 2017 , 52, 854-858	0
643	Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. 2017 , 54, 12-16	2
642	In celebration of Ruggero Ceppellini: HLA in transplantation. 2017 , 89, 71-76	12
641	Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. 2017 , 92, 388-396	17
640	Hematopoietic Cell Transplantation. 2017 , 1-13	1
639	Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. 2017 , 23, 1350-1358	19
638	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. 2017 , 23, 115-124	7
637	Immunotherapy in hematologic malignancies: past, present, and future. 2017 , 10, 94	49
636	Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T-cell subpopulations. 2017 , 57, 1555-1565	18
635	A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. 2017 , 40, 132-139	4
634	Recent advances in T-cell immunotherapy for haematological malignancies. 2017 , 176, 688-704	18
633	Immunomodulatory function of whole human umbilical cord derived mesenchymal stem cells. 2017 , 87, 293-299	10

632	Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. 2017 , 52, 1304-1310	4
631	GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. 2017 , 52, 1261-1267	30
630	Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much. 2017 , 57, 109-111	13
629	Hematopoietic stem cell transplantation and cellular therapy. 2017 , 89, 267-277	18
628	Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. 2017 , 995, 73-95	22
627	Recent Advances in Clinical Cellular Immunotherapy. 2017 , 490-499	
626	Immunotherapy. 2017 ,	4
625	Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future. 2017 , 52, 1241-1248	49
624	Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. 2017 , 102, 184-191	35
623	Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation. 2017 , 40, 691-696	2
622	Next Steps in the CAR Journey of a Thousand Miles. 2017 , 25, 2226-2227	2
621	Choosing the Alternative. 2017 , 23, 1813-1814	10
620	In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation. 2017 , 17, 1401-1415	8
619	How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?. 2017 , 30, 201-211	7
618	Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation. 2017 , 101, 2695-2704	
617	CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy. 2017 , 49, e360	5
616	Physicians - Poster Session. 2017 , 52, S124-S516	0
615	Expression of CD94 by -differentiated NK cells correlates with the and acquisition of cytotoxic features. 2017 , 6, e1346763	4

614	Photochemotherapy and Graft-versus-Leukemia Reaction in Acute Leukemia: Tumor Immunity and Survival Are Dependent on Timing of Photochemotherapy of the Skin. 2017 , 233, 303-313		
613	Hematopoietic Stem Cell Transplantation for Cancer. 2017 , 284-292		
612	Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies. 2017 , 38, 575-593		7
611	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. <i>Blood</i> , 2017 , 130, 2889-2899	2.2	13
610	More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. 2017 , 377, 2102		11
609	Haploidentical Stem Cell Transplantation. 2017 ,		1
608	Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia. 2017 , 15, 959-966		3
607	Protective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia. 2017 , 33, 525-533		3
606	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. 2017 , 23, 278-284		27
605	Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation. 2017 , 23, 87-95		23
604	Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation. 2017 , 31, 663-668		41
603	Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia. 2017 , 98, 177-183		3
602	TcR-depleted haploidentical transplantation results in adult acute leukemia patients. 2017 , 22, 136-144		23
601	Conditional control of suicide gene expression in tumor cells with theophylline-responsive ribozyme. 2017 , 24, 84-91		10
600	Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. 2017 , 176, 431-439		20
599	Autologous Hematopoietic Cell Transplants for Plasma Cell Myeloma: One, Two, or None?. 445-457		
598	Allogeneic Hematopoietic Cell Transplants for Plasma Cell Myeloma. 468-476		
597	Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice. 2017 , 1, 1551-1564		16

596	The number of CD56 NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT. 2017 , 1, 1589-1597	15
595	When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia. 2017 , 6,	5
594	Role of $\text{H}\beta$ Cell Depletion in Prevention of Graft versus Host Disease. 2017 , 5,	20
593	Hitting the Holy Grail of Hematopoietic Cell Transplantation with Naive T-Cell Depleted Allografts-Graft Engineered Hematopoietic Stem Cell Transplant. 2017 , 5,	
592	Preservation of Antigen-Specific Functions of $\text{H}\beta$ Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy. 2017 , 8, 332	1
591	Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. 2017 , 8, 496	92
590	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. 2017 , 8, 573	28
589	Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease. 2017 , 8, 717	23
588	CD28 Blockade Induces Alloantigen-Specific Immune Tolerance but Preserves T-Cell Pathogen Reactivity. 2017 , 8, 1152	8
587	Mucosal-Associated Invariant T Cells Display a Poor Reconstitution and Altered Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation. 2017 , 8, 1861	18
586	A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations. 2017 , 34, 1-9	33
585	Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. 2017 , 35, 1650-1659	169
584	Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?. 2017 , 13, 798-806	10
583	Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India. 2017 , 3, 773-781	9
582	The role of novel immunotherapies in non-Hodgkin lymphoma. 2017 , 6, 93-103	22
581	Stem Cells in Kidney Transplantation: A Review of Chimerism-Based Protocols to Induce Transplantation Tolerance. 2017 , 6, 16-23	
580	Clinical-scale manufacturing of $\text{H}\beta$ cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis. 2018 , 53, 766-769	6
579	Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy. 2018 , 190, 22-31	14

578	T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia. 2018 , 108, 76-84	9
577	The Pharmacology of T Cell Therapies. 2018 , 8, 210-221	51
576	Epidemiology and biology of relapse after stem cell transplantation. 2018 , 53, 1379-1389	39
575	Recipient and donor cells in the graft-versus-solid tumor effect: It takes two to tango. 2018 , 32, 449-456	7
574	Cellular therapies: Day by day, all the way. 2018 , 57, 187-196	11
573	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. 2018 , 33, 581-598	261
572	Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect. 2018 , 7, e1397247	8
571	The doubling potential of T lymphocytes allows clinical-grade production of a bank of genetically modified monoclonal T-cell populations. 2018 , 20, 436-452	2
570	Stem Cell Transplantation for Treatment of Malignancy. 2018 , 201-214	
569	Myeloid Leukemia Vaccines. 2018 , 54-71	
568	No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. 2018 , 53, 383-391	11
567	TNFR2: The new Treg switch?. 2017 , 7, e1373236	12
566	The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. 2018 , 24, 1125-1134	43
565	Historical Perspective and Current Trends in Haploidentical Transplantation. 2018 , 1-11	
564	Adoptive Immunotherapy with Regulatory and Conventional T-cells in Haploidentical T-cell Depleted Transplantation Protects from GvHD and Exerts GvL Effect. 2018 , 43-54	
563	Post-transplant Cyclophosphamide in Haploidentical Transplantation. 2018 , 89-107	
562	Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges. 2018 , 11, 373-389	20
561	Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. 2018 , 24, 1629-1642	24

560	Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community. 2018 , 53, 1170-1179		8
559	Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation. 2018 , 59, 590-600		3
558	HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation. 2018 , 32, 168-175		31
557	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. 2018 , 24, 343-352		46
556	AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses. <i>Blood</i> , 2018 , 131, 131-143	2.2	12
555	Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. 2018 , 93, 222-231		74
554	Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide. 2018 , 24, 119-126		25
553	What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?. 2018 , 283, 166-177		7
552	Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. 2018 , 283, 178-189		17
551	Treating hematological malignancies with cell therapy: where are we now?. 2018 , 18, 65-75		15
550	Comparison of two cytoreductive regimens for T-cell-depleted haploidentical HSCT in pediatric malignancies: Improved engraftment and outcome with TBI-based regimen. 2018 , 65, e26839		8
549	Advances in immunotherapy for pediatric acute myeloid leukemia. 2018 , 18, 51-63		10
548	Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses. 2018 , 1650-1668.e10		0
547	Immunotherapy for Pediatric Malignancies. 2018 ,		
546	Allogeneic Stem Cell Transplantation. 2018 , 39-64		0
545	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. 2018 , 24, 521-528		19
544	Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma. 2018 , 53, 213-218		6
543	. 2018 ,		

542	Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation. 2018 , 9, 2979	6
541	We do still transplant CML, don't we?. 2018 , 2018, 177-184	13
540	Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. 2018 , 183, 364-374	87
539	Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia. 2018 , 9, 2408	2
538	Approaches for generation of anti-leukemia specific T cells. 2018 , 7, 40-44	2
537	NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy. 2018 , 9, 2040	73
536	[What is established in cell therapies? : Possibilities and limits in immuno-oncology]. 2018 , 59, 1230-1238	4
535	Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34-Selected to CD3/CD19-Depleted Grafts in a Retrospective Multicenter Study. 2018 , 9, 1841	10
534	NOTCH and Graft-Versus-Host Disease. 2018 , 9, 1825	8
533	Donor KIR Genotype Impacts on Clinical Outcome after T Cell-Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients. 2018 , 24, 2493-2500	8
532	Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant. 2018 , 2, 2419-2429	9
531	Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. 2018 , 2, 2052-2062	13
530	Fludarabine and neurotoxicity in engineered T-cell therapy. 2018 , 25, 176-191	39
529	Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. 2018 , 53, 1498-1507	7
528	How I treat older patients with acute myeloid leukemia. 2018 , 124, 2472-2483	5
527	Perspective: Biophysical regulation of cancerous and normal blood cell lineages in hematopoietic malignancies. 2018 , 2, 031802	6
526	Transplantation and Transfusion. 2018 , 33-48	
525	Indications and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies in Adults. 2018 , 1596-1607	

524	Human Leukocyte Antigen and Human Neutrophil Antigen Systems. 2018 , 1721-1737.e6		0
523	Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. 2018 , 9, 10		28
522	Restoring T Cell Homeostasis After Allogeneic Stem Cell Transplantation; Principal Limitations and Future Challenges. 2018 , 9, 1237		11
521	Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity. 2018 , 8, 213		55
520	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. 2018 , 4, 1245-1253		53
519	High vs low dose cyclosporine-a, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study. 2018 , 93, E185		
518	Allogene Stammzelltransplantation. 2018 , 13, 128-136		
517	Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review. 2018 , 50, 959-963		
516	Haploidentical Transplantation. 2018 ,		
515	Making HSCs in vitro: don't forget the hemogenic endothelium. <i>Blood</i> , 2018 , 132, 1372-1378	2.2	13
514	Chimerism. 2018 ,		
513	Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study. 2019 , 25, 100-106		5
512	Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders. 2019 , 144, 1135-1146		10
511	The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia. 2019 , 54, 810-814		17
510	History and Current Status of Hematopoietic Cell Transplantation. 2019 , 1-18		
509	Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. 2019 , 66, e27948		9
508	Isolated Extramedullary Relapse as a Poor Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. 2019 , 25, 1756-1760		10
507	The fight against cancer: is harnessing the immune system the ultimate strategy?. 2019 , 80, 568-573		1

506	Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment. 2019 , 42, 101306	9
505	-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy?. 2019 , 8,	22
504	Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma. 2019 , 10, 2235	16
503	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. 2019 , 6, e573-e584	71
502	Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia. 2019 , 13, 667-679	0
501	Potentials of "stem cell-therapy" in pancreatic cancer: An update. 2019 , 19, 1034-1042	10
500	Overview of the Immune Biology of Allogeneic HSCT. 2019 , 1-14	
499	The HLA System in Hematopoietic Stem Cell Transplantation. 2019 , 15-32	1
498	Genetically Engineered T Cell Therapies and Immune System Engagers for Graft-Versus-Host Disease and Graft Versus Leukemia. 2019 , 127-140	
497	T Cell and B Cell Mediated Pathology in Chronic Graft-Versus-Host Disease. 2019 , 251-273	
496	Omics. 2019 , 375-400	
495	Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. 2019 , 25, 1152-1157	9
494	Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy. 2019 , 20,	2
493	Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. 2019 , 25, 1260-1268	11
492	Myeloid malignancies with somatic mutations can be associated with an immunodeficiency phenotype. 2019 , 60, 2025-2033	8
491	Principles of Hematopoietic Stem Cell Transplantation. 2019 , 153-163	0
490	Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease. 2019 , 25, 1965-1969	7
489	A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. 2019 , 10, 609	31

488	IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression. 2019 , 79, 3702-3713	2
487	Cellular therapy for acute myeloid Leukemia - Current status and future prospects. 2019 , 37, 100578	28
486	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. 2019 , 25, 1875-1883	7
485	Chronic graft-versus-host disease and the risk of primary disease relapse: A meta-analysis. 2019 , 74, 33-41	3
484	Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease. 2019 , 10, 295	9
483	Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation. 2019 , 14, e0213739	6
482	Antigen Targets for the Development of Immunotherapies in Leukemia. 2019 , 20,	6
481	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. 2019 , 10, 1065	65
480	Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions. 2019 , 25, 1281-1292	17
479	Concise Review: Boosting T-Cell Reconstitution Following Allogeneic Transplantation-Current Concepts and Future Perspectives. 2019 , 8, 650-657	8
478	Characterization of human natural killer cells for therapeutic use. 2019 , 21, 315-326	1
477	GM-CSF Promotes the Expansion and Differentiation of Cord Blood Myeloid-Derived Suppressor Cells, Which Attenuate Xenogeneic Graft-vs.-Host Disease. 2019 , 10, 183	20
476	Unrelated donor hematopoietic stem cell transplantation for pediatric de novo acute myeloid leukemia with intermediate- or high-risk cytogenetics. 2019 , 23, e13397	1
475	Development of Pre-Engraftment Syndrome, but Not Acute Graft-versus-Host Disease, Reduces Relapse Rate of Acute Myelogenous Leukemia after Single Cord Blood Transplantation. 2019 , 25, 1187-1196	9
474	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. 2019 , 139-158	0
473	Clonal evolution and immune evasion in posttransplantation relapses. 2019 , 2019, 610-616	8
472	Will immune therapy cure acute myeloid leukemia?. 2019 , 1, 2-3	2
471	Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. 2019 , 3, 105-115	18

470	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. 2019 , 3, 670-680	35
469	Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin. 2019 , 3, 1394-1405	5
468	Graft-Versus-Host Disease. 2019 , 2067-2077	
467	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. 2019 , 9, 88	13
466	Prognostic Impact of Blood Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia. 2019 , 3, e167	13
465	Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia. 2019 , 3,	1
464	Maintenance therapy in acute myeloid leukemia: What is the future?. 2019 , 56, 102-109	8
463	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. 2019 , 25, 1128-1135	21
462	Haematopoietic stem cell transplants: principles and indications. 2019 , 80, 33-39	15
461	Allogeneic hematopoietic cell transplantation; the current renaissance. 2019 , 34, 34-44	28
460	CTLA-4 polymorphism rs231775: Influence on relapse and survival after allogeneic hematopoietic stem cell transplantation in childhood. 2019 , 102, 251-255	6
459	ADAMTS-13 activity reduction in plasma of acute myeloid leukemia predicts poor prognosis after bone marrow transplantation. 2019 , 24, 129-133	3
458	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. 2019 , 54, 867-876	4
457	Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas. 2019 , 98, 1237-1247	5
456	A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. 2019 , 54, 1208-1217	16
455	Cancer Immunosurveillance by T Cells. 2019 , 342, 149-173	26
454	Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. 2019 , 56, 183-189	5
453	Five Phases of Recovery and Rehabilitation After Allogeneic Stem Cell Transplantation: A Qualitative Study. 2019 , 42, 50-57	2

452	Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. 2020 , 55, 40-47	19
451	Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. 2020 , 26, 323-332	9
450	Pediatric Autoimmunity and Transplantation. 2020 ,	
449	Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells. 2020 , 34, 895-908	17
448	Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. 2020 , 188, 428-437	5
447	Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. 2020 , 26, 884-892	12
446	The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. 2020 , 67, e28079	9
445	Role of cancer immunology in chronic myelogenous leukemia. 2020 , 88, 106273	13
444	Quantitative Analysis of Thymus-Independent Donor-Derived T Cell Expansion in Transplant Patients. 2020 , 26, 242-253	3
443	Hematopoietic Stem Cell Transplantation. 2020 , 461-469.e3	1
442	Donor sex and recipient outcomes. 2020 , 15, 142-150	0
441	Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients. 2019 , 9,	12
440	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. 2020 , 26, 6475-6482	9
439	Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia. 2020 , 21, e477-e487	11
438	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. 2020 , 8,	2
437	Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation. 2020 , 7, 15-22	1
436	Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. 2020 , 11, 1965	36
435	Microtransplantation for Acute Myeloid Leukemia: A Systematic Review. 2020 , 6, 1614-1620	3

434	Cell interactions in the bone marrow microenvironment affecting myeloid malignancies. 2020 , 4, 3795-3803	16
433	Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease. 2020 , 11, 567210	6
432	Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation. 2020 , 11, 2022	11
431	Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. 2020 , 7, e715-e723	4
430	High-dose cytarabine chemotherapy (â g/m/day) before allogeneic hematopoietic stem cell transplantation for non-core-binding-factor AML in the first complete remission. 2020 , 61, 3128-3136	1
429	Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML. 2020 , 99, 2417-2427	0
428	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. 2020 , 12,	7
427	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. 2020 , 11, 1689	27
426	Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation. 2020 , 26, 6483-6493	3
425	Graft-versus-cancereffect and innovative approaches in the treatment of refractory solid tumors. 2020 , 50, 1697-1706	1
424	Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions. 2020 , 11, 777	0
423	HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation. <i>Blood</i> , 2020 , 136, 362-369	2.2 4
422	Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation. 2020 , 11, 1068	6
421	Insights into the role of the JAK/STAT signaling pathway in graft--host disease. 2020 , 11, 2040620720914489	6
420	Minor Histocompatibility Antigen-Specific T Cells. 2020 , 8, 284	5
419	Prevention of acute graft-versus-host-disease by Withaferin a via suppression of AKT/mTOR pathway. 2020 , 84, 106575	2
418	Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. 2020 , 117, 14331-14341	21
417	Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation. 2020 , 55, 1430-1437	4

416	Alternative Donor Transplantation for Lymphoid Malignancies: How Far We Have Come. 2020 , 38, 1501-1504	1
415	Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data. 2020 , 55, 2008-2016	2
414	Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. 2020 , 11, 147	17
413	Priming of Allo-HLA-DP-Specific Reactivity from the Naïve T Cell Compartment Is Not Exclusively Mediated by Professional Antigen-Presenting Cells. 2020 , 26, 1257-1265	1
412	Alterations of T-cell-mediated immunity in acute myeloid leukemia. 2020 , 39, 3611-3619	17
411	CAR T cells: continuation in a revolution of immunotherapy. 2020 , 21, e168-e178	86
410	Impact of graft-versus-host disease on the clinical outcome of allogeneic hematopoietic stem cell transplantation for non-malignant diseases. 2020 , 111, 869-876	1
409	A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia. 2020 , 4, 40-51	46
408	NFKB1 gene single-nucleotide polymorphisms: implications for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. 2020 , 99, 609-618	1
407	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. 2020 , 34, 1898-1906	7
406	Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. 2020 , 26, 1414-1424	3
405	Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. 2020 , 191, 433-441	22
404	Therapeutic Potential of Cells of the Immune System. 2020 , 41-67	
403	The Changing Landscape of Treatment in Acute Myeloid Leukemia. 2020 , 40, 1-12	5
402	Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing T cell-depleted haploidentical hematopoietic stem cell transplantation. 2021 , 106, 847-858	18
401	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. 2021 , 56, 38-49	2
400	Conventional T cell therapies pave the way for novel Treg therapeutics. 2021 , 359, 104234	2
399	Immunologic recovery and basis for infections in the pediatric hematopoietic stem cell transplant recipient. 2021 , 10-21.e3	

398	Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors. 2021 , 56, 646-654	
397	Development and performance of a next generation sequencing (NGS) assay for monitoring of mixed chimerism. 2021 , 512, 40-48	3
396	New cancer therapies. Are haematopoietic cell transplants a dead duck?. 2021 , 56, 1086-1089	2
395	PD-1 antibody and ruxolitinib enhances graft-versus-lymphoma effect without increasing acute graft-versus-host disease in mice. 2021 , 21, 503-514	2
394	New Approaches to Allogeneic Haematopoietic Cell Transplantation. 2021 , 17, 28	
393	Hematopoietic Stem Cell Sources and Donor Selection. 2021 , 37-54	
392	Relapse After Hematopoietic Cell Transplantation. 2021 , 711-721	
391	Graft-Versus-Host Disease (GvHD) Prophylaxis. 2021 , 153-186	
390	Transplant Pharmacology and Conditioning Therapy. 2021 , 315-346	
389	Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. 2021 , 10,	19
388	Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplant. 2021 , 231-250	
387	The Role of Hematopoietic Stem Cell Transplantation in CML. 2021 , 159-178	
386	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. 2021 , 127, 1598-1605	3
385	Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies. 2021 , 39, 397-418	5
384	Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. 2021 , 113, 840-850	1
383	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. 2021 , 39, 487-498	9
382	Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma. 2021 , 39, 476-486	7
381	Maintenance Therapy in AML. 2020 , 10, 619085	1

380	High preharvest donor Foxp3 mRNA level predicts late relapse of acute lymphoblastic leukaemia after haematopoietic stem cell transplantation. 2021 , 106, 643-653	1
379	Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. 2021 , 11, 60	4
378	Redirecting the Immune Microenvironment in Acute Myeloid Leukemia. 2021 , 13,	4
377	TKI Maintenance After Stem-Cell Transplantation for -ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. 2021 , 12, 630429	2
376	Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation. 2021 , 12, 651751	2
375	Checkpoint-blocked T cells checkmate AML. <i>Blood</i> , 2021 , 137, 3155-3156	2.2
374	GVHD Prophylaxis 2020. 2021 , 12, 605726	11
373	Allogene Blutstammzelltransplantation: Etabliertes und Neues. 2021 , 24, 10-15	
372	Comparison of immune reconstitution between anti-T-lymphocyte globulin and post-transplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. 2021 ,	3
371	DNA and modified vaccinia Ankara prime-boost vaccination generates strong CD8 T cell responses against minor histocompatibility antigen HA-1. 2021 , 195, 433-446	
370	Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta-analysis. 2021 , 39, 448-464	0
369	Dynamical Systems Modeling of Early-Term Immune Reconstitution with Different Anti-Thymocyte Globulin (ATG) Administration Schedules in Allogeneic Stem Cell Transplantation.	
368	Cellular Engineering. 477-499	
367	Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation. 2021 , 11, 643382	5
366	A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. 2021 , 127, 3761-3771	8
365	60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. 2021 , 81, 4373-4384	3
364	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. 2021 , 27, 4825-4835	2
363	Itacitinib prevents xenogeneic GVHD in humanized mice. 2021 , 56, 2672-2681	3

362	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. 2021 , 27, 591-599	2
361	Umbilical cord-derived mesenchymal stem cells promote myeloid-derived suppressor cell enrichment by secreting CXCL1 to prevent graft-versus-host disease after hematopoietic stem cell transplantation. 2021 , 23, 996-1006	1
360	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. 2021 , 27, 921.e1-921.e10	2
359	Biomarkers of graft--host disease: Understanding and applications for the future. 2021 , 11, 335-343	0
358	Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. 2021 , 1-15	1
357	Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation. 2021 , 27, 650-657	0
356	The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. 2021 , 27, 918.e1-918.e9	1
355	Tomotherapy Applied Total Lymphoid Irradiation and Allogeneic Hematopoietic Cell Transplantation Generates Mixed Chimerism in the Rhesus Macaque Model. 2021 , 196, 623-632	1
354	Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation. 2021 , 12, 715909	0
353	GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. 2021 , 1	0
352	Mouse Models of Antigen Presentation in Hematopoietic Stem Cell Transplantation. 2021 , 12, 715893	0
351	Murine Models Provide New Insights Into Pathogenesis of Chronic Graft--Host Disease in Humans. 2021 , 12, 700857	0
350	Oral mucosal graft-versus-host disease and its possibility of antitumor effects. 2022 , 127-150	
349	Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells. 2021 ,	2
348	Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation. 2021 , 11,	0
347	Allogeneic Transplant Overview and Matched Related Donor Transplant. 2021 , 187-221	
346	Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. 2021 , 18, 1172-1185	16
345	MyD88 Costimulation in Donor CD8 T Cells Enhances the Graft-versus-Tumor Effect in Murine Hematopoietic Cell Transplantation. 2021 , 206, 892-903	0

344	Immunotherapy of AML. 2010 , 145, 237-55	2
343	Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation. 2009 , 144, 497-537	4
342	Natural killer cell activity and killer immunoglobulin-like receptors in hematopoietic stem cell transplantation. 2009 , 144, 47-69	3
341	Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation. 2009 , 144, 187-208	2
340	Bone marrow and stem cell transplantation for multiple myeloma. 1999 , 99, 171-94	1
339	Paraneoplastic Autoimmune Reactions. 1999 , 347-369	2
338	Development of allogeneic hematopoietic stem cell transplantation (HSCT). 2002 , 110, 1-37	2
337	Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice. 2002 , 110, 113-36	6
336	Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy. 2002 , 110, 137-47	4
335	Graft versus leukemia in humans. 1995 , 76, 299-314	6
334	Interleukin-2 in bone marrow transplantation. 1995 , 76, 315-36	4
333	Cellular adoptive immunotherapy after bone marrow transplantation. 1995 , 76, 337-69	15
332	Immunotoxins for the therapy of graft versus host disease. 1993 , 68, 133-44	2
331	The role of immunotherapy in the treatment of acute myeloblastic leukemia: from allogeneic bone marrow transplantation to the application of interleukin 2. 1993 , 64, 121-34	3
330	Immune Mediated Tumor Destruction: Challenges for the 1990s. 1992 , 189-195	1
329	Adoptive immunotherapy using donor leukocyte infusions to treat relapsed hematologic malignancies after allogeneic bone marrow transplantation. 1999 , 101, 233-66	2
328	Clinical use of irradiated donor lymphocytes in bone marrow transplantation. 1999 , 101, 267-82	4
327	Engineering hematopoietic grafts using elutriation and positive cell selection to reduce GVHD. 1999 , 101, 311-30	2

326	Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene. 1999 , 101, 369-75	1
325	Haploidentical transplantation. 1999 , 101, 53-77	7
324	Non Myeloablative "Mini Transplants" 1999 , 97-108	32
323	Hematopoietic stem cell transplantation of multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. 1999 , 101, 157-84	8
322	Post-bone marrow transplant use of immunotherapy. 1997 , 77, 27-55	4
321	Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions. 1997 , 77, 57-85	6
320	What Is the Curative Potential of Refractory Leukemia with Related and Unrelated Allogeneic Transplants?. 2000 , 107-117	1
319	Stem Cell Sources. 2004 , 337-356	1
318	T-Cell Depletion to Prevent Graft-vs-Host Disease. 2004 , 431-451	2
317	Nonmyeloablative Transplantation. 2004 , 469-484	1
316	Acute Graft-vs-Host Disease. 2004 , 159-184	1
315	Neurological Complications of Hematopoietic Stem Cell Transplantation. 2008 , 327-352	4
314	Cellular magnetic resonance imaging using superparamagnetic anionic iron oxide nanoparticles: applications to in vivo trafficking of lymphocytes and cell-based anticancer therapy. 2009 , 512, 333-53	21
313	Recent advances in hematopoietic stem cell transplantation and perspectives of RNAi applications. 2010 , 629, 507-23	2
312	Cellular Therapy for Hematology Malignancies: Allogeneic Hematopoietic Stem Transplantation, Graft-Versus-Host Disease, and Graft Versus Leukemia Effects. 2012 , 303-366	1
311	Chronic Myeloid Leukemia "A Brief History. 2007 , 1-13	4
310	The Role of Allogeneic Stem Cell Transplantation in the Therapy of Adult Acute Lymphoblastic Leukemia (ALL). 2008 , 215-228	1
309	Applications of Gene Transfer in Hematologic Malignancy. 1998 , 61-69	2

308	Bone Marrow Transplantation. 1990 , 117-171	1
307	Adoptive Immunotherapy in Human and Canine Chimeras. 1992 , 595-600	2
306	Application of T cell immunotherapy for human viral and malignant diseases. 2000 , 53-73	2
305	Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity. 2013 , 1-28	2
304	Current status of allogeneic and autologous blood and marrow transplantation: Report from the IBMTR and ABMTR in North America. 1996 , 19-34	1
303	Myelodysplastic Syndromes. 2008 , 2235-2259	1
302	Reconstitution of Immunity by Adoptive Immunotherapy with T Cells. 1999 , 137-177	1
301	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. 2009 , 331-402	1
300	Expanded indications for lung transplantation for pulmonary complications after hematopoietic stem cell transplantation. 2020 ,	4
299	Hematopoietic stem cell transplantation. 599-624	2
298	Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT). 2001 , 66, 73-82	16
297	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. 2000 , 111, 18-29	160
296	Chronic myelogenous leukaemia. 2000 , 111, 993-1009	56
295	Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. 2000 , 111, 708-10	25
294	Non-myeloablative stem cell transplants. 2000 , 111, 6-17	86
293	Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. 2000 , 111, 766-773	5
292	Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. 2000 , 111, 1130-7	52
291	Male origin microchimerism and ovarian cancer. 2021 , 50, 87-94	6

290	Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. 1999 , 11, 87-95	60
289	Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. 1996 , 61, 738-45	52
288	Graft-versus-host reactivity and graft-versus-leukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation. 1996 , 61, 826-30	10
287	Characterization of baboon class I major histocompatibility molecules. Implications for baboon-to-human xenotransplantation. 1996 , 61, 989-96	16
286	Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299. 1996 , 62, 721-9	10
285	Adoptive immunotherapy in canine chimeras. 1997 , 63, 430-6	54
284	Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. 1997 , 64, 297-302	26
283	Predictive value of host-specific donor helper T-cell precursor frequency for acute graft-versus-host disease and relapse in HLA-identical siblings receiving allogeneic bone marrow transplantation for hematological malignancies. 1997 , 64, 1147-52	21
282	Possible induction of graft-versus-leukemia effect against a leukemia refractory to antileukemia response in ordinary MHC-compatible, allogeneic bone marrow transplantation. 1998 , 65, 893-8	1
281	Selective CD4+ T-cell depletion does not prevent graft-versus-host disease. 1998 , 66, 138-41	14
280	Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. 1998 , 66, 620-5	56
279	T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. 2001 , 71, 433-9	78
278	Emerging applications of gene transfer in the hematopoietic cancers. 1997 , 19, 1-6	9
277	Minitransplants and cell-based therapies for malignant and nonmalignant disorders. 1999 , 4, 184-188	5
276	Combination Therapy With Chemotherapy, Donor Lymphocyte Infusion With Concurrent Blinatumomab in Relapsed/Refractory Acute Precursor B-Lymphoblastic Leukemia. 2021 , 43, e280-e283	1
275	Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. 1997 , 157, 111-23	50
274	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. 2018 , 3,	70
273	T cell optimization for graft-versus-leukemia responses. 2020 , 5,	8

272	Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. 2016 , 1,	31
271	Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. 2000 , 106, 705-14	102
270	LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. 2001 , 107, 1581-9	230
269	Alternative mechanisms that mediate graft-versus-host disease in allogeneic hematopoietic cell transplants. 2020 , 130, 4532-4535	1
268	Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. 2003 , 112, 1688-96	373
267	Pleasant memories: remembering immune protection while forgetting about graft-versus-host disease. 2003 , 112, 25-7	14
266	Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. 2010 , 120, 2370-8	73
265	Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. 2013 , 123, 3756-65	65
264	IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. 1999 , 104, 317-25	144
263	CAR therapy: the CD19 paradigm. 2015 , 125, 3392-400	158
262	Differential requirements for myeloid leukemia IFN- γ conditioning determine graft-versus-leukemia resistance and sensitivity. 2017 , 127, 2765-2776	11
261	Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response. 2017 , 127, 517-529	57
260	Non-myeloablative transplantation. 2002 , 392-421	35
259	Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy. 2000 , 2000, 356-375	1
258	Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy. 2000 , 2000, 356-375	2
257	New Developments in the Therapy of Acute Myelocytic Leukemia. 2000 , 2000, 69-89	2
256	Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors. 2003 , 2003, 372-397	9
255	Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. 2012 , 2012, 143-151	52

254	Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?. 2012 , 2012, 246-250		10
253	Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant. <i>Blood</i> , 1997 , 89, 3864-3872	2.2	3
252	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997 , 89, 3880-3887	2.2	3
251	Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect. <i>Blood</i> , 1997 , 90, 1694-1700	2.2	5
250	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. <i>Blood</i> , 1998 , 91, 3671-3680	2.2	9
249	Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoablation for the Treatment of Malignant and Nonmalignant Hematologic Diseases. <i>Blood</i> , 1998 , 91, 756-763	2.2	23
248	Cytotoxic T-Lymphocyte-Defined Human Minor Histocompatibility Antigens With a Restricted Tissue Distribution. <i>Blood</i> , 1998 , 91, 2197-2207	2.2	10
247	Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection. <i>Blood</i> , 1998 , 92, 4581-4590	2.2	3
246	Autologous Stem Cell Transplantation in Acute Myelocytic Leukemia. <i>Blood</i> , 1998 , 92, 1073-1090	2.2	1
245	Expansion of Philadelphia Chromosome-Negative CD3+CD56+ Cytotoxic Cells From Chronic Myeloid Leukemia Patients: In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease Mice. <i>Blood</i> , 1998 , 92, 3318-3327	2.2	4
244	Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. <i>Blood</i> , 1999 , 94, 1201-1208	2.2	6
243	A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. <i>Blood</i> , 2000 , 95, 3693-3701	2.2	6
242	Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. <i>Blood</i> , 2000 , 96, 1047-1055	2.2	8
241	Introduction - The Graft-Versus-Leukemia Effect. 2000 ,		2
240	Minor Histocompatibility Antigens in GVL. 2000 ,		1
239	Practical Implementation of the Continual Reassessment Method. 2005 , 97-116		1
238	Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation. 2017 , 6, 617		14
237	Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. 2011 , 6, e23217		17

236	Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study. 2017 , 12, e0169512	19
235	Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation. 2015 , 38, 966-74	7
234	“Less is More” The Role of Purging in Hematopoietic Stem Cell Transplantation. 1997 , 2, 268-274	3
233	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. 2017 , 8, 49548-49563	23
232	High copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. 2017 , 8, 87944-87954	14
231	Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. 2009 , 1, 599-621	51
230	Stem cells derived from cord blood in transplantation and regenerative medicine. 2009 , 106, 831-6	17
229	Translational and clinical advances in acute graft-versus-host disease. 2020 , 105, 2550-2560	6
228	Hematopoietic stem cell transplantation : overview for general pediatrician. 2007 , 50, 613	5
227	The Role of Immune Checkpoints after Cellular Therapy. 2020 , 21,	4
226	Enhancement of Graft-versus-leukemia Effects by Mesenchymal Stem Cells in Mixed Chimerism after a Murine Non-myeloablative Hematopoietic Stem Cell Transplantation. 2008 , 43, 219	2
225	Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience. 2017 , 6, 1	0
224	Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer. 2016 , 6, 675-681	3
223	Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 2020 , 18, 599-634	11
222	Graft versus tumor effect against neuroblastoma: a case report with long-term survival and a review of the literature. 2014 , 3, 97-101	1
221	Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL). 2021 , 181, 179-196	0
220	Dynamical Systems Modeling of Early-Term Immune Reconstitution with Different Antithymocyte Globulin Administration Schedules in Allogeneic Stem Cell Transplantation. 2021 ,	0
219	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. 2021 , 12, 6071	5

- 218 Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation Is a Good Choice for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis of Randomized Controlled Trials. **2021**, 11, 708727 1
- 217 NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. **2021**, 11, 751183 1
- 216 Minor histocompatibility antigens as targets for T-cell immunotherapy. **2021**, 66, 322-345
- 215 Clinical and Basic Science Studies of Human Umbilical Cord Blood. **2000**,
- 214 Leukemia-Reactive T Cells in Adoptive Immunotherapy for Relapsed Leukemia After Allogeneic Transplantation. **2000**,
- 213 Adoptive Allogeneic Cell-Mediated Immunotherapy and Nonmyeloablative Stem-Cell Transplantation. **2000**,
- 212 New Strategies in the Use of Bone Marrow (or Hematopoietic Stem Cell) Transplantation to Treat Cancers of the Blood. **2000**, 253-265
- 211 Bibliography Articles Cited in Commentaries. **2000**, 1023-1058 0
- 210 Effector Cells and Mechanisms of the GVL Effect. **2000**,
- 209 GVL Effects in Human Marrow Stem-Cell Transplants. **2000**,
- 208 Current Status of Blood and Marrow Transplantation. **2000**, 11-21
- 207 New Developments in the Therapy of Acute Myelocytic Leukemia. **2000**, 2000, 69-89 2
- 206 Adoptive Allogeneic Cell-Mediated Immunotherapy and Nonmyeloablative Stem-Cell Transplantation. **2000**, 267-278
- 205 Bone Marrow Transplantation for Cancer and Autoimmunity. **2000**, 409-421
- 204 Separating GVHD and GVL Reactions. **2000**,
- 203 Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy. **2000**, 185-193
- 202 Nonmyeloablative Allogeneic Stem Cell Transplantation: Towards Improving Efficacy of Immunotherapy Instead of Myeloablative Chemoradiotherapy. **2000**, 112-117
- 201 Adoptive Immunotherapy of Human Diseases with Antigen-Specific T-Cell Clones. **2000**, 29-44

- 200 The GVL Effect in Donor Lymphocyte Transfusion. **2000**,
- 199 Experimental Animal Models in the Study of GVL Reactions. **2000**,
- 198 Should All Adult Patients with Acute Lymphoblastic Leukemia in First Remission Undergo Allogeneic Bone Marrow Transplantation?. **2000**, 95-105
- 197 New Strategies for Hematopoietic Stem Cell Transplantation. **2000**, 97-111 1
- 196 Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. *Blood*, **2000**, 95, 2426-2433 2.2 1
- 195 Exploring the potential for graft vs. tumor response in a combine bone marrow and liver transplantation for large hepatocellular carcinoma. **2000**, 69, 2003-4
- 194 Cord blood banking and stem cell transplantation: implications for the practicing Ob/Gyn. **2000**, 55, 263-4
- 193 Mononuclear Cell Preparations. **2001**, 179-186
- 192 Leukemia. **2001**, 287-300
- 191 The New York Blood Center's Placental/Umbilical Cord Blood Program. Experience with a 'new' source of hematopoietic stem cells for transplantation. **2001**, 47-70 2
- 190 Blood and Marrow Transplantation. **2001**, 295-341
- 189 Shifting Towards Better Immunotherapy Rather Than More Intensive Chemoradiotherapy Using a Non-Myeloablative Approach in Patients with Leukemia. **2001**, 674-677
- 188 Adoptive Immunotherapy of Acute Leukemia and Acute Phase Chronic Myeloid Leukemia after Allogeneic Bone Marrow Transplantation. **2001**, 665-673
- 187 Immunotherapeutic strategies Kathleen NS Cathcart, Javier Pinilla, David A Scheinberg. **2001**, 523-536
- 186 Stammzelltherapie mit fetalen Zellen. **2002**, 165-182
- 185 Commentary on Section II. **2002**, 182-190
- 184 Biotherapeutics: Current Status and Future Directions. **2003**, 281-324
- 183 Nonmyeloablative Allogeneic Transplantation. **2003**, 169-188

182 Allogeneic Effector Cell Populations. **2003**, 387-410

181 Intensification of the Conditioning Regimen for Patients with high-risk AML and MDS: 3 year Experience of using an 188 Re α -Labelled anti α CD 66 Monoclonal Antibody. **2003**, 43-58

180 Allogeneic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia. **2003**, 29-46

179 Transplantation Strategies for High Risk Acute Myeloid Leukemias. **2003**, 469-472

178 Non-Hodgkin's Lymphoma. **2003**, 83-99

177 Donor Leukocyte Infusions. **2003**, 287-310

176 Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia. **2003**, 483-484

175 Blutstammzell- und Knochenmarktransplantation. **2003**, 1121-1133

174 Natural Killer Cells in Transplantation: Friends or Foes?. **2004**, 343-353

173 Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia. **2004**, 25-45

172 Models for Biomarkers and Minimal Residual Tumor. **2004**, 243-258

171 Hematopoietic Stem Cell Transplantation for Solid Tumors. **2004**, 739-743

170 Donor Lymphocyte Infusions. **2004**, 453-469

169 Hochdosistherapie und Stammzelltransplantation. **2004**, 535-562

168 Allogeneic transplantation and treatment with donor lymphocytes. **2004**, 260-274

167 Cancer α Hematologic Disorders. **2005**, 473-480

166 Second allogeneic hematopoietic stem cell transplantation in children to overcome graft failure or relapse after initial transplant. **2006**, 49, 1329

165 Morphological Variation of Ten Ipomoea Species of Bangladesh. **2006**, 9, 1714-1719

- 164 Cellular Immunotherapeutic Approaches to the Hematopoietic Stem-Cell Transplant Patient. **2006**, 211-222
- 163 Acute Lymphocytic Leukemia in Adults. **2008**, 2191-2213
- 162 Donor Lymphocyte Infusions Clinical Applications and the Graft-versus-Leukemia Effect. **2008**, 687-710
- 161 Hematopoietic Stem Cell Transplantation. **2008**, 501-512 1
- 160 Graft Manipulation: T Cell Depletion and Tumor Cell Purging. **2008**, 653-686
- 159 Distribution of CD4+CD25+ T cells and graft-versus-host disease in human hematopoietic stem cell transplantation. **2008**, 51, 1336
- 158 Stem Cell Sources for Allogeneic Transplantation. **2008**, 225-244
- 157 The impact of cyclosporine on graft-versus-host disease and relapse rate after allogeneic hematopoietic stem cell transplantation in children with leukemia. **2008**, 25, 1-9
- 156 Hematopoietic stem cell transplantation in children and adolescents with malignant disease. **2009**, 144, 455-96
- 155 Evolving indications for hematopoietic stem cell transplantation in multiple myeloma and other plasma cell disorders. **2009**, 144, 317-55
- 154 Allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia. **2009**, 144, 441-54 2
- 153 Bone marrow T cells are superior to splenic T cells to induce chimeric conversion after non-myeloablative bone marrow transplantation. **2009**, 24, 252-62 2
- 152 Immunotherapy of Cancer. **2009**, 209-240 1
- 151 Dendritic Cell Homeostasis: Physiology and Impact on Disease. **2010**, 161-212
- 150 Hematopoietic Cell Transplantation from Partially HLA-Mismatched (HLA-Haploidentical) Related Donors. **2010**, 299-343
- 149 Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia in Adults. **2010**, 193-202
- 148 Augmentation of Hematopoietic Stem Cell Transplantation with Anti-cancer Vaccines. **2010**, 855-867
- 147 The Role of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia Patients in the Era of Tyrosine Kinase Inhibitors. **2010**, 53-74

- 146 Acute Toxicities, Late Sequelae, and Quality of Survivorship in Children with Acute Myeloid Leukemia: The Impact of Allogeneic Stem Cell Transplant. **2011**, 265-282
- 145 Hematopoietic Stem Cell Transplantation in Philadelphia-Positive Acute Lymphoblastic Leukemia. **2011**, 305-313
- 144 Molecular Therapies. **2011**, 257-275
- 143 Immunotherapy for Acute Lymphocytic Leukemia. **2011**, 351-363
- 142 Current Status of BoneMarrow Transplantation for Treatment of Cancer. **2011**, 407-435
- 141 The Role of Hematopoietic Stem-Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. 250-258
- 140 Biomaterial Surfaces for the Isolation of Hematopoietic Stem and Progenitor Cells. **2012**, 3-17
- 139 Cellular Engineering for the Production of New Blood Components. 492-520
- 138 The Effect of Pretreatment with Chemotherapeutic Drugs on the Susceptibility to Lymphokine Activated CD8+ T Lymphocyte- Mediated Cytotoxicity in CMK Leukemia Cells.
- 137 Recent Advances in Clinical Cellular Immunotherapy. 473-479
- 136 Preparative Regimens. **2014**, 41-56
- 135 Acute Myeloid Leukemia. **2014**, 221-249
- 134 Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Biology, Indications, and Outcomes. **2014**, 171-220
- 133 Hematopoietic Stem Cell Transplantation. **2014**, 485-492.e2
- 132 Bone Marrow Transplantation. **1991**, 68-77
- 131 Bone Marrow Stem Cells: Purification and Clinical Results. **1991**, 113-118
- 130 Eradication of leukaemic marrow and prevention of leukaemia relapse with total body irradiation and bone marrow transplantation. **1991**, 8, 189-201
- 129 Chronic Graft-Versus-Host Disease. **1992**, 237-256

128 Impact of Total Body Irradiation and Marrow Transplantation in Early and Advanced Leukemia. **1992**, 537-542

127 THERAPEUTIC POTENTIAL OF CYTOKINES AND PEPTIDES IN IRRADIATION-INDUCED MYELOSUPPRESSION. **1992**, 834-838

126 Immune Therapy of Human Cancers. **1992**, 13-17

125 Two Murine Leukemia Models for the Investigation of New Treatment Strategies in Bone Marrow Transplantation. **1992**, 555-562

124 Graft-Versus Leukemia Activity in Experimental Bone Marrow Transplantation: The Impact of Natural Killer Cells and Graft-Versus-Host Disease. **1994**, 709-716

123 IBMTR Analysis of Results of Bone Marrow Transplantation in Acute Leukemia. **1994**, 681-685

122 Use of Roquinimex in the Myeloid Leukemias. **1996**, 285-293

121 Interleukin-2 Bolus Infusion as Consolidation Therapy in 2nd Remission of Acute Myelocytic Leukemia. **1996**, 312-316

120 Natural Killer Cell Alloreactivity Against Acute Leukemia Blasts: The Level of Activity Depends on the Individual Target-Effector Pair. **1996**, 298-305

119 Cellular Immunotherapy of Acute Leukemias After High Dose Chemotherapy with Cytarabine (ARA-C) and Cyclophosphamide (CY) in a Murine Model. **1996**, 306-311

118 Bone marrow transplantation. **1996**, 3-12

117 Immunopharmacology and Immunotherapy of Human Cancer. **1996**, 53-101

116 Adoptive Immunotherapy in Chimeras. **1997**, 57-76

115 Bone Marrow Transplantation for Acute Myelogenous Leukemia. **1997**, 807-809

114 Use of Interferon- β in the Treatment of Chronic Myelogenous Leukemia. **1997**, 47-66

113 Models for Minimal Residual Tumor. **1997**, 183-196

112 HLA Class II Restricted T-Cell Reactivity to a Developmentally Regulated Antigen Shared by Leukemic Cells and CD34+ Early Progenitor Cells. *Blood*, **1997**, 90, 1083-1090

2.2 1

111 Donor Immunization Vaccination and Transfer of Donor Immunity to Bone Marrow Transplant Recipients in the Course of Allogeneic Cell Therapy for Prevention and Treatment of Relapse. **1998**, 71-80

110 Stem Cell Transplants for Hematopoietic Malignancies. **1998**, 505-521

109 Early Allogeneic Transplantation Favorably Influences the Outcome of Adult Patients Suffering from Acute Myeloid Leukemia. **1998**, 1097-1102

108 Induction of Graft-versus-Leukemia-Activity after Peripheral Blood Progenitor Cell Transplantation (PBPCT). **1998**, 685-692

107 Transfer of porcine MHC DRalpha into IEalpha-deficient murine bone marrow results in reduced IE-restricted Vbeta usage. **1998**, 66, 1081-8

106 Bone Marrow Transplantation for Children Less Than 2 Years of Age With Acute Myelogenous Leukemia or Myelodysplastic Syndrome. *Blood*, **1998**, 92, 3546-3556 2.2

105 Prevention and Treatment of Relapse. **1999**, 93-99

104 Chronic Graft-Versus-Host Disease. **1999**, 183-198

103 Blutstammzell- und Knochenmarktransplantation. **1999**, 1440-1451

102 Gene Marking of T Lymphocytes. **1999**, 189-199

101 Differential Enhancement of Graft-Versus-Host (GVH) and Graft-Versus-Leukemia (GVL) Reactions by Interleukin-12 (IL-12). **1999**, 83-89

100 Summary and Future Directions. **1999**, 323-349

99 Feasibility of Immunotherapy of Relapsed Leukemia With Ex Vivo-generated Cytotoxic T Lymphocytes Specific for Hematopoietic System-Restricted Minor Histocompatibility Antigens. *Blood*, **1999**, 93, 2336-2341 2.2 14

98 Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation. *Blood*, **1999**, 93, 2738-2747 2.2 5

97 Granulocyte Colony-Stimulating Factor-mobilized Allogeneic Stem Cell Transplantation Maintains Graft-Versus-Leukemia Effects Through a Perforin-Dependent Pathway While Preventing Graft-Versus-Host Disease. *Blood*, **1999**, 93, 4071-4078 2.2 4

96 Peripheral Blood Stem Cell Transplantation From Unrelated Donors: A Comparison With Marrow Transplantation. *Blood*, **1999**, 94, 455-464 2.2

95 Indications for Hematopoietic Transplantation for AML. **2015**, 777-797

94 Hematopoietic Stem Cell Transplantation and Lymphodepletion for the Treatment of Cancer. **2015**, 189-201

93 In Vitro Generation of Cytotoxic CD4 Lymphocyte Response against Autologous Acute Myeloid Leukemia. **2015**, 3,

92 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

91 Immunotherapy for acute leukemia. **2015**, 7, 354-5

90 The Functional Capacities of Peripheral Blood Regulatory T Cells after an Allogeneic Stem Cell Transplant Correlate with the Risk of Graft-Versus-Host Disease. **2016**, 2, 25-29

89 Graft Versus Leukemia (GvL), Graft Versus Lymphoma Effect in Haploidentical SCT. **2017**, 95-102

88 Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma. **2019**, 231-243

87 «Graft-Versus-Host» Disease after Haploidentical Hematopoietic Stem Cell Transplantation from Relative Donors in Children with Cancer, Prophylaxis Regimens and Correlation with «Graft-Versus-Tumor» Effect: a Retrospective Cohort Study. **2019**, 6, 113-122

86 T-Lymphoblastic Lymphoma. **2020**, 223-227

85 Immunopathology and Immunotherapy of Myeloid Leukemia. **2020**, 103-117

84 A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. **2021**, 111, 106737

83 Immunology and Immunotherapy of Graft-Versus-Host Disease. **2020**, 557-574

82 Die besondere Therapiesituation. **2020**, 211-243

81 Allogeneic Transplant Overview and Matched Related Donor Transplant. **2020**, 1-34

80 Transplant Pharmacology and Conditioning Therapy. **2020**, 1-32

79 Immunotherapy in Pediatric Hematologic Malignant Neoplasms. **2020**, 27, 14-21

78 Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. **2021**,

77 Hematopoietic Stem Cells and Regeneration. **2021**,

76 Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. **2021**, 6,

75 Biologic Principles of Hematopoietic Stem Cell Transplantation. **2006**, 91-105

- 74 Blutstammzell- und Knochenmarktransplantation. **2005**, 1179-1191
- 73 Replantation of marrow and hematopoietic stem cells from normal donors. **1997**, 17-23
- 72 Hematopoietic Stem Cell Transplantation: Allogeneic Immunotherapy for Cancer. **2008**, 495-503
- 71 Immune Therapy of Chronic Myelogenous Leukemia. **2007**, 185-200
- 70 Hematopoietic Stem Cell Transplantation and Lymphodepletion for the Treatment of Cancer. **2021**, 143-156
- 69 Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor. **2021**, 11, 772862 2
- 68 Clinical trials: design, endpoints and interpretation of outcomes.. **2022**, 0
- 67 Human multipotent adult progenitor cells effectively reduce graft-vs-host disease while preserving graft-vs-leukemia activity. **2021**, 39, 1506-1519 1
- 66 DNA methylation: a saga of genome maintenance in hematological perspective.. **2022**, 35, 448 1
- 65 Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients.. **2022**, 12, 19 0
- 64 The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML.. **2022**, 0
- 63 Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. **2022**, 405-430
- 62 Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants.. **2022**, 0
- 61 Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to Graft Versus Host Disease management.. **2022**, 71, 101524 0
- 60 CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.. **2022**, 14, eabg8027 2
- 59 Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients.. **2022**,
- 58 Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans.. **2022**, 13, 805177 0
- 57 Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation.. **2022**, 23,

56	Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model.. 2022 , 13, 844271		
55	Promiscuity of Peptides Presented in HLA-DP Molecules from Different Immunogenicity Groups Is Associated With T-Cell Cross-Reactivity.. 2022 , 13, 831822		0
54	Graft-Versus-Solid-Tumor Effect: From Hematopoietic Stem Cell Transplantation to Adoptive Cell Therapies.. 2022 ,		0
53	HLA-DQ Heterodimers in Hematopoietic-Cell Transplantation.. <i>Blood</i> , 2022 ,	2.2	0
52	Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?. 2022 , 10, 796994		
51	Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.. 2022 ,		0
50	Treatment of AML Relapse After Allo-HCT.. 2021 , 11, 812207		3
49	High-dose therapy and posttransplantation symptom burden: striking a balance. 224-236		
48	Data_Sheet_1.PDF. 2020 ,		
47	Higher recipient pre-transplant FOXP3 mRNA expression is associated with acute leukaemia relapse after HSCT.		
46	Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies.. 2022 ,		1
45	Oral Chronic Graft-Versus-Host Disease. 2022 , 3,		
44	CAR-T Cells and Recent Advances in Clinical Cellular Immunotherapy. 2022 , 543-553		
43	Clinical Characteristics and Outcome Analysis for HLA Loss Patients Following Partially Mismatched Related Donor Transplantation Using HLA Chimerism for Loss of Heterozygosity Analysis by Next-Generation Sequencing. 2022 , 31, 096368972211029		0
42	Naive T Cells in Graft Versus Host Disease and Graft Versus Leukemia: Innocent or Guilty?. 13,		1
41	Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation.		
40	Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia.		0
39	Immune landscape after allo-HSCT: TIGIT and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. <i>Blood</i> ,	2.2	1

38	Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. 2022 , 100991	1
37	Blockade of PD-1/PD-L1 increases effector T cells and aggravates murine chronic graft-versus-host disease. 2022 , 110, 109051	1
36	BONE MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES AND CANCER. 1996 , 16, 393-427	
35	Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. 2022 , 11, 2249	1
34	The mythological chimera and new era of relapse prediction post-transplant. 2022 , 100997	0
33	Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic SCT is predictive of subsequent relapse and survival.	
32	Haploidentical hematopoietic stem cell transplantation in severe aplastic anemia: time for long term and quality of life assessed studies. 2022 ,	
31	Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT.	
30	Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. 2022 , 25, 104859	2
29	CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies. 13,	1
28	Current Progress of CAR-NK Therapy in Cancer Treatment. 2022 , 14, 4318	0
27	Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses. 2022 ,	0
26	Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation.	0
25	Ligand-based discovery of a novel GATA2 inhibitor targeting acute myeloid leukemia cells. 2,	0
24	CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission. 2022 , 6, e788	0
23	T Cell Immunotherapy of Cancer. 1-13	0
22	ACUTE MYELOID LEUKEMIA: CURRENT APPROACHES TO DIAGNOSIS AND TREATMENT (literature review). 2011 , 29-34	0
21	Newest Approaches in Immunotherapy for Non-Hodgkinâs Lymphoma. 40-48	0

- 20 Controversies and expectations for the prevention of GVHD: A biological and clinical perspective. **2023**, 13, 0
- 19 **Abstract** of Immunotherapy in Hematological Malignancies **Promise and Perils**. 0
- 18 What a **"harmless"** antibiotic can teach us about GVL. **2022**, 140, 2420-2422 0
- 17 Photochemical Treatment with 5-FU Psoralen and Ultraviolet A Light to Control the Fate of Naive or Primed T Lymphocytes In Vivo After Allogeneic Bone Marrow Transplantation. **1999**, 163, 5145-5156 9
- 16 Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. 0
- 15 Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach. **2022**, 0
- 14 Transplantation. **2023**, 599-674 0
- 13 GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT. **2023**, 16, 0
- 12 Immunotherapy for Hematological Cancers. **2023**, 1-15 0
- 11 Platelet-Derived Mitochondria Attenuate 5-FU-Induced Injury to Bone-Associated Mesenchymal Stem Cells. **2023**, 2023, 1-20 0
- 10 Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation. **2023**, 0
- 9 Enforced gut homing of murine regulatory T cells reduces early graft-versus-host disease severity. **2023**, 0
- 8 Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia. **2023**, 0
- 7 Effect of changes in lymphocyte subsets at diagnosis in acute myeloid leukemia on prognosis: association with complete remission rates and relapse free survivals. 0
- 6 Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database. **2023**, 102, 1215-1227 0
- 5 Can Immune Therapy Cure Acute Myeloid Leukemia?. 0
- 4 An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment. **2023**, 24, 6031 0
- 3 Stem cells in perinatal medicine. **2023**, 0

- 2 Donor selection for allogeneic hematopoietic cell transplantation. ○
- 1 Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation. ○